<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:65.1pt;left:56.7pt;line-height:9.5pt"><span style="font-family:WpftstAdvTT99c4c969,serif;font-size:9.5pt;color:#131313">REVIEW ARTICLE</span></p>
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,661.3334,97.333339)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAADgAAAA4CAYAAACohjseAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAABCElEQVR4nO3P4W7BABiF4XP/l0XWoVPBTDqiTI0YhujQtTtzE8vi
TU/yfL+/V4ZP//3AX68KvPdVgfe+KvDexw/8KUuTqSgLk6kovk2mPM9Npvx6NZku
l7PJdP7KTKYsy0ym0+lkMh2PB5PpcNybTPv9p8m0221Npu12YzJtNh8m03q9NplW
q5XJboFLk2m5fDeZFovUZErTuck0n7+ZTLPZzGSaTqcmU5IkJtMkmZhM4/HYZPzA
0ejVZIrj2GQaDocm08vtkGkwGJhMz/2+ydTr9UymbrdrMnU6kckURZHJ1G63Taan
MDSZwlbLZGo1myZTo9EwmR6DwGQKggeTqV6vm0y1Ws1kvyuNGoQau4OYAAAAAElF
TkSuQmCC">
<p style="top:109.7pt;left:51.0pt;line-height:16.0pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:16.0pt;color:#131313">Bone marrow concentrate injections for the treatment</span></p>
<p style="top:127.7pt;left:51.0pt;line-height:16.0pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:16.0pt;color:#131313">of osteoarthritis: evidence from preclinical findings to the clinical</span></p>
<p style="top:145.6pt;left:51.0pt;line-height:16.0pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:16.0pt;color:#131313">application</span></p>
<p style="top:180.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:WpftstAdvTT99c4c969,serif;font-size:10.0pt;color:#131313">Carola Cavallo</span><sup><span style="font-family:WpftstAdvTT99c4c969,serif;font-size:7.0pt;color:#131313">1</span></sup><sup><span style="font-family:ThgbpfAdvP0005,serif;font-size:8.0pt;color:#131313"> </span></sup><span style="font-family:ThgbpfAdvP0005,serif;font-size:8.0pt;color:#131313">&amp;</span><span style="font-family:WpftstAdvTT99c4c969,serif;font-size:10.0pt;color:#131313"> Angelo Boffa</span><sup><span style="font-family:WpftstAdvTT99c4c969,serif;font-size:7.0pt;color:#131313">2,3</span></sup></p>
<p style="top:181.7pt;left:201.9pt;line-height:8.0pt"><span style="font-family:ThgbpfAdvP0005,serif;font-size:8.0pt;color:#131313">&amp;</span><span style="font-family:WpftstAdvTT99c4c969,serif;font-size:10.0pt;color:#131313"> Luca Andriolo</span><sup><span style="font-family:WpftstAdvTT99c4c969,serif;font-size:7.0pt;color:#131313">2</span></sup><sup><span style="font-family:ThgbpfAdvP0005,serif;font-size:8.0pt;color:#131313"> </span></sup><span style="font-family:ThgbpfAdvP0005,serif;font-size:8.0pt;color:#131313">&amp;</span><span style="font-family:WpftstAdvTT99c4c969,serif;font-size:10.0pt;color:#131313"> Simone Silva</span><sup><span style="font-family:WpftstAdvTT99c4c969,serif;font-size:7.0pt;color:#131313">2,3</span></sup><sup><span style="font-family:ThgbpfAdvP0005,serif;font-size:8.0pt;color:#131313"> </span></sup><span style="font-family:ThgbpfAdvP0005,serif;font-size:8.0pt;color:#131313">&amp;</span><span style="font-family:WpftstAdvTT99c4c969,serif;font-size:10.0pt;color:#131313"> Brunella Grigolo</span><sup><span style="font-family:WpftstAdvTT99c4c969,serif;font-size:7.0pt;color:#131313">1</span></sup><sup><span style="font-family:ThgbpfAdvP0005,serif;font-size:8.0pt;color:#131313"> </span></sup><span style="font-family:ThgbpfAdvP0005,serif;font-size:8.0pt;color:#131313">&amp;</span><span style="font-family:WpftstAdvTT99c4c969,serif;font-size:10.0pt;color:#131313"> Stefano Zaffagnini</span><sup><span style="font-family:WpftstAdvTT99c4c969,serif;font-size:7.0pt;color:#131313">2,3</span></sup><sup><span style="font-family:ThgbpfAdvP0005,serif;font-size:8.0pt;color:#131313"> </span></sup><span style="font-family:ThgbpfAdvP0005,serif;font-size:8.0pt;color:#131313">&amp;</span></p>
<p style="top:192.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:WpftstAdvTT99c4c969,serif;font-size:10.0pt;color:#131313">Giuseppe Filardo</span><sup><span style="font-family:WpftstAdvTT99c4c969,serif;font-size:7.0pt;color:#131313">4</span></sup></p>
<p style="top:222.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:GrpgmnAdvTTc488b0e6,serif;font-size:8.5pt;color:#131313">Received: 30 April 2020 /Accepted: 3 July 2020</span></p>
<p style="top:231.7pt;left:51.0pt;line-height:8.5pt"><span style="font-family:GdslvcAdvPi3,serif;font-size:8.5pt;color:#131313">#</span><span style="font-family:GrpgmnAdvTTc488b0e6,serif;font-size:8.5pt;color:#131313"> The Author(s) 2020</span></p>
<p style="top:255.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:LfwwglAdvTTaf7f9f4f.B,serif;font-size:10.0pt;color:#131313">Abstract</span></p>
<p style="top:267.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:10.0pt;color:#131313">Purpose</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> To investigate the available literature on the use of bone marrow aspirate concentrate (BMAC) and summarize the</span></p>
<p style="top:280.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">current evidence supporting its potential for the injective treatment of joints affected by osteoarthritis (OA).</span></p>
<p style="top:292.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:10.0pt;color:#131313">Methods</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> A systematic literature search was conducted on three electronic databases (PubMed, Embase, and Cochrane Library)</span></p>
<p style="top:304.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">in April 2020, using the following string:</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313"> &#x201c;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">((bone marrow concentrate) OR (BMC) OR (bone marrow aspirate concentrate) OR</span></p>
<p style="top:317.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(BMAC)) AND (osteoarthritis)</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x201d;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">, and inclusion criteria: clinical and preclinical (animal) studies of any level of evidence, written</span></p>
<p style="top:329.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">in English language, and evaluating the intra-articular or subchondral use of BMAC for the injective treatment of OA joints.</span></p>
<p style="top:341.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:10.0pt;color:#131313">Results</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> The publication trend remarkably increased over time. A total of 22 studies were included in the qualitative data synthesis:</span></p>
<p style="top:353.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">four preclinical studies and 18 clinical studies, for a total number of 4626 patients. Safety was documented by all studies, with a low</span></p>
<p style="top:366.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">number of adverse events. An overall improvement in pain and function was documented in most of the studies, but the clinical</span></p>
<p style="top:378.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">studies present significant heterogeneity, few patients, short-term follow-up, and overall poor methodology.</span></p>
<p style="top:390.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:10.0pt;color:#131313">Conclusion</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> There is a growing interest in the field of BMAC injections for the treatment of OA, with promising results in</span></p>
<p style="top:403.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">preclinical and clinical studies in terms of safety and effectiveness. Nevertheless, the current knowledge is still preliminary.</span></p>
<p style="top:415.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Preclinical research is still needed to optimize BMAC use, as well as high-level large controlled trials to better understand the real</span></p>
<p style="top:428.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">potential of BMAC injections for the treatment of patients affected by OA.</span></p>
<p style="top:453.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:10.0pt;color:#131313">Keywords</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> Bone marrow concentrate </span><sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">. </span></sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">BMAC </span><sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">. </span></sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Injective </span><sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">. </span></sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Intra-articular </span><sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">. </span></sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Osteoarthritis </span><sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">. </span></sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Cartilage</span></p>
<p style="top:490.8pt;left:51.0pt;line-height:12.0pt"><span style="font-family:LfwwglAdvTTaf7f9f4f.B,serif;font-size:12.0pt;color:#131313">Introduction</span></p>
<p style="top:517.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Osteoarthritis (OA) is a degenerative disease characterized by</span></p>
<p style="top:529.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">progressive deterioration and loss of articular cartilage with con-</span></p>
<p style="top:542.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">comitant structural and functional changes in the entire joint [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">1</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">].</span></p>
<p style="top:492.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Its incidence and prevalence are rising, in particular among older</span></p>
<p style="top:504.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">adults in developed countries, likely related to the aging of the</span></p>
<p style="top:517.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">population and increasing obesity [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">2</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">4</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Clinical features of OA</span></p>
<p style="top:529.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">are mostly characterized by signs and symptoms of inflammation,</span></p>
<p style="top:542.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">including pain, effusions, stiffness, and loss of mobility, often</span></p>
<p style="top:554.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">associated with significant functional impairment [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">5</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Current</span></p>
<p style="top:567.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">management strategies include weight loss, physical treatments,</span></p>
<p style="top:579.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">oral medications, such as non-steroidal anti-inflammatory drugs</span></p>
<p style="top:592.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">and acetaminophen, and intra-articular injection therapies with</span></p>
<p style="top:604.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">corticosteroids and hyaluronic acid (HA) [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">6</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Nevertheless, these</span></p>
<p style="top:616.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">treatment options mainly provide symptom relief rather than</span></p>
<p style="top:629.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">disease-modifying changes to the intra-articular environment [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">7</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">].</span></p>
<p style="top:641.8pt;left:317.5pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">The use of orthobiologics is gaining increasing interest due</span></p>
<p style="top:654.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">to the availability of new promising products to address OA.</span></p>
<p style="top:666.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Among these, platelet concentrates are now considered a suit-</span></p>
<p style="top:679.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">able option to treat OA, with results going beyond the mere</span></p>
<p style="top:691.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">placebo effects expected for injective treatments and higher</span></p>
<p style="top:704.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">than those provided by other traditional products, although</span></p>
<p style="top:583.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:LdpwkhAdvTT4ff65459,serif;font-size:8.5pt;color:#131313">*</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Angelo Boffa</span></p>
<p style="top:593.5pt;left:66.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">angeloboffa@libero.it</span></p>
<p style="top:620.1pt;left:51.0pt;line-height:6.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:6.0pt;color:#131313">1</span></p>
<p style="top:621.9pt;left:65.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Laboratorio RAMSES, IRCCS Istituto Ortopedico Rizzoli, Via di</span></p>
<p style="top:631.9pt;left:65.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Barbiano, 1/10, 40136 Bologna, Italy</span></p>
<p style="top:645.0pt;left:51.0pt;line-height:6.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:6.0pt;color:#131313">2</span></p>
<p style="top:646.8pt;left:65.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Clinica Ortopedica e Traumatologica II, IRCCS Istituto Ortopedico</span></p>
<p style="top:656.8pt;left:65.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Rizzoli, Via Pupilli, 1, 40136 Bologna, Italy</span></p>
<p style="top:670.0pt;left:51.0pt;line-height:6.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:6.0pt;color:#131313">3</span></p>
<p style="top:671.7pt;left:65.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Alma Mater Studiorum - Universit&#xe0; di Bologna, Via Zamboni, 33,</span></p>
<p style="top:681.7pt;left:65.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">40126 Bologna, Italy</span></p>
<p style="top:694.9pt;left:51.0pt;line-height:6.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:6.0pt;color:#131313">4</span></p>
<p style="top:696.6pt;left:65.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Applied and Translational Research (ATR) Center, IRCCS Istituto</span></p>
<p style="top:706.6pt;left:65.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Ortopedico Rizzoli, Via di Barbiano, 1/10, Bologna, Italy</span></p>
<p style="top:44.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:GrpgmnAdvTTc488b0e6,serif;font-size:8.5pt">https://doi.org/10.1007/s00264-020-04703-w</span></p>
<p style="top:223.0pt;left:203.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">/ Published online: 13 July 2020</span></p>
<p style="top:33.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">International Orthopaedics (2021) 45:525&#x2013;538</span></p>


<p style="top:58.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">with still suboptimal outcomes [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">8</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 9</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. More recently, mesen-</span></p>
<p style="top:70.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">chymal stromal cells (MSCs) have been proposed as a prom-</span></p>
<p style="top:83.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ising alternative for OA treatment thanks to their structural</span></p>
<p style="top:95.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">contribution to tissue repair and even more their immunomod-</span></p>
<p style="top:108.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ulatory and anti-inflammatory actions, through direct cell-to-</span></p>
<p style="top:120.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cell interaction or secretion of bioactive factors [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">10</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 11</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">].</span></p>
<p style="top:133.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">MSCs can be easily isolated from various tissues, such as</span></p>
<p style="top:145.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">bone marrow, adipose tissue, synovial membrane, peripheral</span></p>
<p style="top:158.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">blood, and skin [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">12</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Bone marrow MSCs (BMSCs) were the</span></p>
<p style="top:170.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">first type of MSCs to be identified and, due to the ease of</span></p>
<p style="top:182.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">collection, bone marrow currently represents a commonly</span></p>
<p style="top:195.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">used source of MSCs [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">13</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. In particular, this type of MSCs</span></p>
<p style="top:207.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">has been either applied as a cell suspension after being ex-</span></p>
<p style="top:220.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">panded by culture or used as a simple bone marrow concen-</span></p>
<p style="top:232.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">trate (BMC), thanks to their relative abundance [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">14</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">].</span></p>
<p style="top:245.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Considering the strict regulations and the problems related to</span></p>
<p style="top:257.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cell manipulation and expansion, cultured BMSCs have been</span></p>
<p style="top:270.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">widely explored in the preclinical setting, but their use is ex-</span></p>
<p style="top:282.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tremely limited in clinical practice, both in Europe and in the</span></p>
<p style="top:294.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">USA [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">15</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">19</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Conversely, the minimal cell manipulation ap-</span></p>
<p style="top:307.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">proach, allowing to obtain a bone marrow aspirate concentrate</span></p>
<p style="top:319.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(BMAC) directly on site in a one-step treatment, has been</span></p>
<p style="top:332.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">widely utilized in the clinical practice for the treatment of</span></p>
<p style="top:344.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cartilage lesions first and, more recently, has been proposed</span></p>
<p style="top:357.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">as a promising injective approach to treat degenerative ortho-</span></p>
<p style="top:369.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">paedic conditions [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">20</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 21</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Nevertheless, the real potential of</span></p>
<p style="top:382.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">BMAC as intra-articular OA treatment remains controversial</span></p>
<p style="top:394.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">[</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">22</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">].</span></p>
<p style="top:407.0pt;left:62.4pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">The aim of this systematic review was to examine the avail-</span></p>
<p style="top:419.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">able literature on the use of BMAC, evaluating preclinical and</span></p>
<p style="top:431.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">clinical studies, in order to summarize the current evidence</span></p>
<p style="top:444.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">supporting its potential for the injective treatment of joints affect-</span></p>
<p style="top:456.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ed by OA. The hypothesis of the current study was that the</span></p>
<p style="top:469.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">available preclinical studies support the rationale for the injective</span></p>
<p style="top:481.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">use of BMAC, and that an increasing number of clinical studies</span></p>
<p style="top:494.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">reports safety and effectiveness of this biological approach.</span></p>
<p style="top:530.0pt;left:51.0pt;line-height:12.0pt"><span style="font-family:LfwwglAdvTTaf7f9f4f.B,serif;font-size:12.0pt;color:#131313">Material and methods</span></p>
<p style="top:556.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">A systematic review of the literature was performed on the use</span></p>
<p style="top:568.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of BMAC as injective treatment for joints affected by OA. A</span></p>
<p style="top:581.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">literature search was conducted on three electronic databases</span></p>
<p style="top:593.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(PubMed, Embase, and Cochrane Library) on April 20th,</span></p>
<p style="top:606.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">2020, with no time limitation and without any filters, using</span></p>
<p style="top:618.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the following string:</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313"> &#x201c;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">((bone marrow concentrate) OR (BMC)</span></p>
<p style="top:631.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">OR (bone marrow aspirate concentrate) OR (BMAC)) AND</span></p>
<p style="top:643.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(osteoarthritis)</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x201d;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">. According to the Preferred Reporting Items</span></p>
<p style="top:656.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">for Systematic Reviews and Meta-Analysis (PRISMA) and</span></p>
<p style="top:668.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Cochrane guidelines [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">23</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], the article selection and data extrac-</span></p>
<p style="top:681.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tion process were conducted separately by two authors (AB</span></p>
<p style="top:693.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">and SS). The initial title and abstract screenings were made</span></p>
<p style="top:705.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">using the following inclusion criteria: clinical and preclinical</span></p>
<p style="top:58.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(animal) studies of any level of evidence, written in English</span></p>
<p style="top:70.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">language, and evaluating the intra-articular or subchondral use</span></p>
<p style="top:83.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of BMAC for the injective treatment of joints with OA.</span></p>
<p style="top:95.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Exclusion criteria consisted of articles written in other lan-</span></p>
<p style="top:108.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">guages, literature reviews, basic science in vitro articles, case</span></p>
<p style="top:120.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">reports, congress abstracts, studies on joint diseases different</span></p>
<p style="top:133.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">from OA, studies on other BMAC applications (e.g., use as</span></p>
<p style="top:145.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">augmentation to other surgical techniques), and studies deal-</span></p>
<p style="top:158.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ing only with expanded or otherwise manipulated MSCs. In</span></p>
<p style="top:170.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the second step, the full texts of the selected articles were</span></p>
<p style="top:182.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">screened, with further exclusion according to the previously</span></p>
<p style="top:195.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">described criteria. Additionally, all references from the select-</span></p>
<p style="top:207.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ed papers and previously published relevant reviews were also</span></p>
<p style="top:220.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">screened. Two investigators independently reviewed each ar-</span></p>
<p style="top:232.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ticle (AB and SS), and any discrepancies between them were</span></p>
<p style="top:245.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">resolved by discussion and consensus. For the included stud-</span></p>
<p style="top:257.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ies, relevant data were extracted from article texts, tables, and</span></p>
<p style="top:270.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">figures, and then summarized and analyzed according to the</span></p>
<p style="top:282.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">purpose of the present work. In particular, the following data</span></p>
<p style="top:294.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">were collected for preclinical studies: year of publication, an-</span></p>
<p style="top:307.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">imals evaluated, joint involved, OA model, types of treatment,</span></p>
<p style="top:319.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">BMAC harvest site and characteristics, follow-up length, eval-</span></p>
<p style="top:332.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">uation methods, and results. For clinical studies, the following</span></p>
<p style="top:344.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">data were collected: year of publication, study design, joint</span></p>
<p style="top:357.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">involved, treatment type and schedule, BMAC manufacturing</span></p>
<p style="top:369.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">and characteristics, number of evaluated subjects, subject</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2019;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">s</span></p>
<p style="top:382.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">characteristics, follow-up length, main results, and adverse</span></p>
<p style="top:394.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">events.</span></p>
<p style="top:407.0pt;left:317.5pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">The effectiveness of BMAC injective therapy was evaluat-</span></p>
<p style="top:419.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ed by summarizing the reported benefits, while the safety of</span></p>
<p style="top:431.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the procedures was evaluated identifying the reported side</span></p>
<p style="top:444.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">effects. To assess the methodological quality of the included</span></p>
<p style="top:456.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">clinical studies, the subscales of a Coleman Methodology</span></p>
<p style="top:469.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Score, modified by Kon et al. [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">24</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], were determined for each</span></p>
<p style="top:481.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">study by two separate authors (AB and SS). In case of dis-</span></p>
<p style="top:494.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">agreement between the two authors, divergences were</span></p>
<p style="top:506.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">discussed and a consensus was reached.</span></p>
<p style="top:542.5pt;left:306.1pt;line-height:12.0pt"><span style="font-family:LfwwglAdvTTaf7f9f4f.B,serif;font-size:12.0pt;color:#131313">Results</span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">The flowchart of the article selection process is reported in</span></p>
<p style="top:581.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Fig.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 1</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">. After duplicates were removed, the initial search iden-</span></p>
<p style="top:593.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tified 2027 records, whose abstracts were screened and select-</span></p>
<p style="top:606.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ed according to the inclusion/exclusion criteria. Four articles</span></p>
<p style="top:618.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">were identified through the reference lists, which gave a total</span></p>
<p style="top:631.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of 29 articles assessed for eligibility. However, five studies</span></p>
<p style="top:643.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">were excluded being congress abstracts, one study was ex-</span></p>
<p style="top:656.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cluded because it was a case report [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">25</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], and one study was</span></p>
<p style="top:668.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">excluded because it provided the same data of another includ-</span></p>
<p style="top:681.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ed study [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">26</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Thus, a total of 22 studies were included in the</span></p>
<p style="top:693.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">qualitative data synthesis: 4 preclinical studies [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">27</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">30</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] and 18</span></p>
<p style="top:705.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">clinical studies [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">31</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">48</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Since the first reports in 2014, the</span></p>
<p style="top:33.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">526</span></p>
<p style="top:33.5pt;left:369.1pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">International Orthopaedics (SICOT) (2021) 45:525&#x2013;538</span></p>


<p style="top:407.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">publication trend remarkably increased over time, especially</span></p>
<p style="top:419.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">for the clinical studies, with over 50% of the articles published</span></p>
<p style="top:431.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">from 2018 (Fig.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 2</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">).</span></p>
<p style="top:459.7pt;left:51.0pt;line-height:11.0pt"><span style="font-family:NsmfbfAdvTTa351d857.B,serif;font-size:11.0pt;color:#131313">Preclinical studies</span></p>
<p style="top:485.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">The potential of BMAC for the injective OA treatment has been</span></p>
<p style="top:497.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tested in 4 animal studies (Table</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 1</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">). All of them were compar-</span></p>
<p style="top:510.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ative studies investigating the results of BMAC in knee OA</span></p>
<p style="top:522.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">models against placebo (saline), HA, platelet-rich plasma</span></p>
<p style="top:407.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(PRP), and cultured BMSCs. Knee OA was induced by anterior</span></p>
<p style="top:419.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cruciate ligament transection in all four studies, also associated</span></p>
<p style="top:431.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">with meniscectomy in two studies. Bone marrow was harvested</span></p>
<p style="top:444.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">from the iliac crest in three studies and from the proximal tibia</span></p>
<p style="top:456.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">in one study. The used animals included rabbit (two studies),</span></p>
<p style="top:469.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">sheep, and goat (one study each), which were sacrificed from</span></p>
<p style="top:481.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">six to 20 weeks after the intra-articular injections, and then</span></p>
<p style="top:494.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">evaluated through macroscopic and radiologic evaluation, his-</span></p>
<p style="top:506.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tological examination, and immunohistochemical analysis.</span></p>
<p style="top:519.1pt;left:317.5pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">The macroscopic evaluation of articular cartilage was de-</span></p>
<p style="top:531.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">scribed in three studies, all showing better results in animals</span></p>
<p style="top:544.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">treated with BMAC compared with control groups. Song et al.</span></p>
<p style="top:556.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">[</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">29</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] and Singh et al. [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">30</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] reported less severe cartilage dete-</span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">rioration compared with saline. In addition, beside showing</span></p>
<p style="top:581.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the benefits vs. saline, Wang et al. [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">28</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] documented in the</span></p>
<p style="top:593.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">BMAC group only focal and superficial cartilage erosion</span></p>
<p style="top:606.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">and mild osteophyte development with respect to the PRP</span></p>
<p style="top:618.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">group, where obvious extensive and full-thickness cartilage</span></p>
<p style="top:631.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">defects combined with marked osteophyte development were</span></p>
<p style="top:643.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">reported. Singh et al. [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">30</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] performed also a radiological eval-</span></p>
<p style="top:656.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">uation, confirming the positive results by showing less severe</span></p>
<p style="top:668.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">signs of OA (including osteophyte formation, subchondral</span></p>
<p style="top:681.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">bone sclerosis, and articular surface irregularity) when isolat-</span></p>
<p style="top:693.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ed non-cultured BMSCs were injected compared with saline.</span></p>
<img style="position:absolute;transform:matrix(.3199204,0,-0,.31967528,-267.17134,513.33279)" src="data:image/jpeg;base64,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">
<p style="top:697.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:8.5pt;color:#131313">Fig. 2</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Cumulative number of preclinical and clinical studies on BMAC</span></p>
<p style="top:707.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">injective OA treatment</span></p>
<img style="position:absolute;transform:matrix(.319938,0,-0,.31977118,-281.37263,-384.62196)" src="data:image/png;base64,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">
<p style="top:56.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:8.5pt;color:#131313">Fig. 1</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Flowchart showing the</span></p>
<p style="top:66.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">systematic review selection</span></p>
<p style="top:76.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">process</span></p>
<p style="top:33.5pt;left:532.3pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">527</span></p>
<p style="top:33.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">International Orthopaedics (SICOT) (2021) 45:525&#x2013;538</span></p>


<p style="top:707.1pt;left:145.7pt;line-height:8.5pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:8.5pt;color:#131313">Table 1</span></p>
<p style="top:672.1pt;left:145.8pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Preclinical studies</span></p>
<p style="top:707.1pt;left:164.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Author and</span></p>
<p style="top:707.1pt;left:174.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">year</span></p>
<p style="top:648.7pt;left:164.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Animal and OA</span></p>
<p style="top:648.7pt;left:174.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">model</span></p>
<p style="top:582.8pt;left:164.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Joint</span></p>
<p style="top:539.3pt;left:164.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Treatment</span></p>
<p style="top:446.0pt;left:164.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Harvest site</span></p>
<p style="top:382.6pt;left:164.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">BMAC characteristics</span></p>
<p style="top:289.5pt;left:164.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Follow-up and evaluation</span></p>
<p style="top:196.2pt;left:164.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Results</span></p>
<p style="top:707.1pt;left:195.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Desando G</span></p>
<p style="top:698.6pt;left:205.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">et al. 2018</span></p>
<p style="top:698.6pt;left:215.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">[</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">27</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">]</span></p>
<p style="top:648.7pt;left:195.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Rabbit (48 knees)</span></p>
<p style="top:640.2pt;left:205.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">OA induced by</span></p>
<p style="top:640.2pt;left:215.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ACL</span></p>
<p style="top:640.2pt;left:224.9pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">transection</span></p>
<p style="top:582.8pt;left:195.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Knee</span></p>
<p style="top:539.4pt;left:195.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">12 BMAC vs. 12 cultured</span></p>
<p style="top:530.8pt;left:205.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">BMSCs vs. 12 BMAC +</span></p>
<p style="top:530.8pt;left:215.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">HA vs.</span></p>
<p style="top:539.3pt;left:224.9pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">12 cultured BMMCs + HA</span></p>
<p style="top:539.3pt;left:234.9pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Single IA injection</span></p>
<p style="top:446.1pt;left:195.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Iliac crest</span></p>
<p style="top:382.7pt;left:195.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Centrifugation</span></p>
<p style="top:374.2pt;left:205.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">procedure</span></p>
<p style="top:374.2pt;left:214.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">at 400</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313">g</span></p>
<p style="top:374.2pt;left:224.9pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">for 10 min at 20 &#xb0;C</span></p>
<p style="top:382.7pt;left:231.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">2 &#xd7; 10</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:6.0pt;color:#131313">6</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> cells/ml</span></p>
<p style="top:289.5pt;left:195.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">8 weeks</span></p>
<p style="top:289.5pt;left:205.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Cell biodistribution,</span></p>
<p style="top:280.9pt;left:215.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">histologic,</span></p>
<p style="top:280.9pt;left:224.9pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">immunohistochemical,</span></p>
<p style="top:280.9pt;left:234.9pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">and synovial fluid</span></p>
<p style="top:280.9pt;left:244.9pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">analysis</span></p>
<p style="top:196.2pt;left:195.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">BMAC showed effectiveness for the injective</span></p>
<p style="top:187.7pt;left:205.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">OA treatment, with similar results than</span></p>
<p style="top:187.7pt;left:215.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">BMSCs and better results for the</span></p>
<p style="top:187.7pt;left:224.9pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">association of BMAC + HA.</span></p>
<p style="top:707.1pt;left:254.9pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Wang Z et al.</span></p>
<p style="top:698.6pt;left:264.8pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">2018 [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">28</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">]</span></p>
<p style="top:648.7pt;left:254.9pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Goat (24 knees)</span></p>
<p style="top:640.2pt;left:264.8pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">OA induced by</span></p>
<p style="top:640.2pt;left:274.8pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ACL</span></p>
<p style="top:640.2pt;left:284.7pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">transection and</span></p>
<p style="top:640.2pt;left:294.7pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">meniscectomy</span></p>
<p style="top:582.8pt;left:254.9pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Knee</span></p>
<p style="top:539.3pt;left:254.9pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">6 BMAC vs. 6 saline</span></p>
<p style="top:530.8pt;left:264.8pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">vs. 6 PRP</span></p>
<p style="top:539.3pt;left:274.8pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Three IA injections</span></p>
<p style="top:530.8pt;left:284.7pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(once every 4 weeks)</span></p>
<p style="top:446.1pt;left:254.9pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Iliac crest</span></p>
<p style="top:382.7pt;left:254.9pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Two-step centrifugation</span></p>
<p style="top:374.2pt;left:264.8pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">procedure</span></p>
<p style="top:382.7pt;left:273.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">5 ml with 1190.3 &#xd7; 10</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:6.0pt;color:#131313">6</span></p>
<p style="top:374.2pt;left:284.7pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">cells/ml</span></p>
<p style="top:289.5pt;left:254.9pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">6 weeks</span></p>
<p style="top:289.5pt;left:264.8pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Macroscopic, histologic,</span></p>
<p style="top:280.9pt;left:274.8pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">immunohistochemical,</span></p>
<p style="top:280.9pt;left:284.7pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">and synovial fluid</span></p>
<p style="top:280.9pt;left:294.7pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">analysis</span></p>
<p style="top:196.2pt;left:254.9pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Higher cartilage protection in the BMAC</span></p>
<p style="top:187.7pt;left:264.8pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">group than both PRP and saline groups.</span></p>
<p style="top:707.1pt;left:304.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Song F et al.</span></p>
<p style="top:698.6pt;left:314.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">2014 [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">29</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">]</span></p>
<p style="top:648.7pt;left:304.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Sheep (18 knees)</span></p>
<p style="top:640.2pt;left:314.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">OA induced by</span></p>
<p style="top:640.2pt;left:324.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ACL</span></p>
<p style="top:640.2pt;left:334.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">transection and</span></p>
<p style="top:640.2pt;left:344.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">meniscectomy</span></p>
<p style="top:582.8pt;left:304.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Knee</span></p>
<p style="top:539.3pt;left:304.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">6 BMSCs vs. 6 saline</span></p>
<p style="top:530.8pt;left:314.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">vs. 6 cultured MSCs</span></p>
<p style="top:539.3pt;left:324.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Single IA injection</span></p>
<p style="top:446.1pt;left:304.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Iliac crest</span></p>
<p style="top:382.7pt;left:304.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">BMSCs were isolated by</span></p>
<p style="top:374.2pt;left:314.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">density gradient</span></p>
<p style="top:374.2pt;left:324.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">centrifugation, and were</span></p>
<p style="top:374.2pt;left:334.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">resuspended in PBS</span></p>
<p style="top:382.7pt;left:343.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">5 ml with 0.9 &#xd7; 10</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:6.0pt;color:#131313">6</span></p>
<p style="top:374.2pt;left:354.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">cells/ml</span></p>
<p style="top:289.5pt;left:304.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">8 weeks</span></p>
<p style="top:289.5pt;left:314.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Macroscopic,</span></p>
<p style="top:280.9pt;left:324.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">histopathologic, ELISA</span></p>
<p style="top:280.9pt;left:334.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">and proteoglycan assay,</span></p>
<p style="top:280.9pt;left:344.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">RT-PCR analysis of</span></p>
<p style="top:280.9pt;left:354.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">cartilage</span></p>
<p style="top:196.2pt;left:304.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">BMSCs and cultured MSCs provided both</span></p>
<p style="top:187.7pt;left:314.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">good results in terms of macroscopic and</span></p>
<p style="top:187.7pt;left:324.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">histologic findings, GAG protection,</span></p>
<p style="top:187.7pt;left:334.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">cytokines, and cartilage biomarkers</span></p>
<p style="top:187.7pt;left:344.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">changes.</span></p>
<p style="top:707.1pt;left:364.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Singh A et al.</span></p>
<p style="top:698.6pt;left:374.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">2014 [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">30</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">]</span></p>
<p style="top:648.7pt;left:364.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Rabbit (20 knees)</span></p>
<p style="top:640.2pt;left:374.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">OA induced by</span></p>
<p style="top:640.2pt;left:384.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ACL</span></p>
<p style="top:640.2pt;left:394.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">transection</span></p>
<p style="top:582.8pt;left:364.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Knee</span></p>
<p style="top:539.3pt;left:364.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">10 BMSCs vs. 10</span></p>
<p style="top:530.8pt;left:374.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">saline</span></p>
<p style="top:539.3pt;left:384.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Single IA injection</span></p>
<p style="top:446.1pt;left:364.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Proximal tibia</span></p>
<p style="top:382.7pt;left:364.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">BMSCs were isolated by</span></p>
<p style="top:374.2pt;left:374.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">density gradient</span></p>
<p style="top:374.2pt;left:384.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">following Pittenger</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2019;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">s</span></p>
<p style="top:374.2pt;left:394.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">method</span></p>
<p style="top:382.7pt;left:400.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1 ml with 1 &#xd7; 10</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:6.0pt;color:#131313">6</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> cells/ml</span></p>
<p style="top:289.5pt;left:364.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">20 weeks</span></p>
<p style="top:289.5pt;left:374.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Macroscopic, radiologic,</span></p>
<p style="top:280.9pt;left:384.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">and histopathologic</span></p>
<p style="top:278.2pt;left:394.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">analysis</span></p>
<p style="top:196.2pt;left:364.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">BMSCs provided significant</span></p>
<p style="top:187.7pt;left:374.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">histopathological and radiological</span></p>
<p style="top:187.7pt;left:384.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">improvement compared with control</span></p>
<p style="top:187.7pt;left:394.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">group.</span></p>
<p style="top:707.1pt;left:433.9pt;line-height:8.5pt"><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313">ACL</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> anterior cruciate ligament;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> BMAC</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> bone marrow aspirate concentrate;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> BMSCs</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> bone marrow mesenchymal stromal cells;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> ELISA</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> enzyme-linked immunosorbent assay;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> HA</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> hyaluronic acid;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> IA</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> intra-</span></p>
<p style="top:707.1pt;left:443.9pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">articular;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> MSCs</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> mesenchymal stromal cells;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> PBS</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> phosphate-buffered saline;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> PRP</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> platelet-rich plasma;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> RT-PCR</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> real-time polymerase chain reaction</span></p>
<p style="top:33.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">528</span></p>
<p style="top:33.5pt;left:369.1pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">International Orthopaedics (SICOT) (2021) 45:525&#x2013;538</span></p>


<p style="top:58.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">The histological analysis was performed in all studies,</span></p>
<p style="top:70.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">reporting better results in the BMAC group, with degenerative</span></p>
<p style="top:83.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">changes and articular cartilage erosion limited within the su-</span></p>
<p style="top:95.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">perficial layer, normal chondrocyte density, and abundant ex-</span></p>
<p style="top:108.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tracellular matrix preserved in the lower layers. Interestingly</span></p>
<p style="top:120.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Desando et al. [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">27</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] in a rabbit model demonstrated similar</span></p>
<p style="top:133.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">results with respect to the use of cultured BMSCs and better</span></p>
<p style="top:145.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">histological findings in joints treated with the combination of</span></p>
<p style="top:158.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">BMAC and HA with respect to BMAC alone. Moreover, they</span></p>
<p style="top:170.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">underlined the cell homing pattern: MSCs preferentially mi-</span></p>
<p style="top:182.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">grated toward tissue areas showing OA features in the menis-</span></p>
<p style="top:195.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cus and cartilage, and near inflammatory zones in the synovial</span></p>
<p style="top:207.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">membrane, and the combination with HA contributed to boost</span></p>
<p style="top:220.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cell migration toward articular cartilage. Desando et al. [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">27</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]</span></p>
<p style="top:232.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">also investigated immunohistochemical characteristics, show-</span></p>
<p style="top:245.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ing a downregulation of type I collagen and TNF-</span><span style="font-family:YbpclkAdvTT3713a231+03,serif;font-size:10.0pt;color:#131313">&#x3b1;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> in articu-</span></p>
<p style="top:257.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">lar cartilage after BMAC treatment. Finally, Song et al. [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">29</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]</span></p>
<p style="top:270.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">evaluated GAG content showing an increase in the proteogly-</span></p>
<p style="top:282.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">can concentration in the cellular treatment groups. Moreover,</span></p>
<p style="top:294.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">they analyzed the gene expression of Col2A1, Aggrecan, and</span></p>
<p style="top:307.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">MMP-13 underlining a significant increase in Col2A1 and</span></p>
<p style="top:319.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Aggrecan, and a decrease in MMP-13 in both non-cultured</span></p>
<p style="top:332.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">BMSC and cultured MSC groups compared with the saline</span></p>
<p style="top:344.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">group.</span></p>
<p style="top:368.9pt;left:51.0pt;line-height:11.0pt"><span style="font-family:NsmfbfAdvTTa351d857.B,serif;font-size:11.0pt;color:#131313">Clinical studies</span></p>
<p style="top:394.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Out of the 18 clinical articles found (Table</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 2</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">), six were retro-</span></p>
<p style="top:407.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">spective case series, five were retrospective comparative stud-</span></p>
<p style="top:419.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ies, four were randomized controlled trials (RCTs), and three</span></p>
<p style="top:432.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">were prospective case series. Eleven studies focused on knee</span></p>
<p style="top:444.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">OA [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">31</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">41</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], two focused on hip OA [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">42</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 43</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], two focused on</span></p>
<p style="top:456.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">shoulder OA [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">44</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 45</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], while the other three studies described</span></p>
<p style="top:469.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">several joints affected by OA [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">46</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">48</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Intra-articular BMAC</span></p>
<p style="top:481.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">injections were performed in 17 studies, while in one study</span></p>
<p style="top:494.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">[</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">36</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], the injection was performed within the tibial and femoral</span></p>
<p style="top:506.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">subchondral bone of the knee. The most common injection</span></p>
<p style="top:519.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">schedule was the single injection (16 articles), while a</span></p>
<p style="top:531.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">four injection schedule was studied in two articles [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">37</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 42</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">].</span></p>
<p style="top:544.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">In 11 studies, BMAC was the only product injected, while in</span></p>
<p style="top:556.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the other seven studies, other products were combined includ-</span></p>
<p style="top:568.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ing PRP, platelet lysate, or minimally processed adipose tis-</span></p>
<p style="top:581.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">sue. In the nine studies with control groups, the effectiveness</span></p>
<p style="top:593.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of BMAC was compared with other injective treatments such</span></p>
<p style="top:606.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">as PRP, micro-fragmented adipose tissue, whole bone mar-</span></p>
<p style="top:618.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">row, cultured MSCs, placebo, or other treatments such as ex-</span></p>
<p style="top:631.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ercise and total knee arthroplasty. The BMAC harvest site was</span></p>
<p style="top:643.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the anterior-superior (ASIS) or postero-superior iliac spine</span></p>
<p style="top:656.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(PSIS) (14 PSIS, 3 ASIS, and 1 ASIS or PSIS). The total</span></p>
<p style="top:668.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">number of subjects included and treated with BMAC injec-</span></p>
<p style="top:681.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tions was 4626, and the mean trial duration was 20 months,</span></p>
<p style="top:693.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ranging from two months to 12 years of follow-up, with all but</span></p>
<p style="top:705.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">one study [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">36</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] lasting less than 2.5 years. The evaluation with</span></p>
<p style="top:58.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the modified Coleman Methodology Score showed an overall</span></p>
<p style="top:70.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">poor methodology of the included studies, with an average</span></p>
<p style="top:83.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">score of 36.6 points out of 100 (range 23</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">60), as reported in</span></p>
<p style="top:95.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Table</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 2</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">.</span></p>
<p style="top:108.1pt;left:317.5pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">The main finding of the included studies was an overall</span></p>
<p style="top:120.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">improvement in pain and function in OA patients treated</span></p>
<p style="top:133.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">with BMAC injections, with similar results obtained for</span></p>
<p style="top:145.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the different joints evaluated. However, the comparative</span></p>
<p style="top:158.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">studies were not able to prove superiority over the other</span></p>
<p style="top:170.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">intra-articular options and, in the only placebo-blinded</span></p>
<p style="top:182.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">RCT [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">33</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], BMAC did not show superiority over saline</span></p>
<p style="top:195.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">at 12 months of follow-up. On the other hand, intra-</span></p>
<p style="top:207.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">articular BMAC injections (combined with platelet prod-</span></p>
<p style="top:220.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ucts) demonstrated better results than exercise therapy in</span></p>
<p style="top:232.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">knee OA patients at 24 months of follow-up [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">35</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], and</span></p>
<p style="top:245.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">subchondral BMAC injections reported similar results</span></p>
<p style="top:257.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">compared with total knee arthroplasty in younger patients</span></p>
<p style="top:270.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">with knee OA secondary to corticosteroid-related</span></p>
<p style="top:282.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">osteonecrosis at an average of 12 years of follow-up [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">36</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">].</span></p>
<p style="top:294.9pt;left:317.5pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Shaw et al. [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">37</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] underlined the importance of the injection</span></p>
<p style="top:307.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">schedule, suggesting that multiple BMAC injections can be</span></p>
<p style="top:319.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">more effective than a single injection, and reported additional</span></p>
<p style="top:332.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">benefit with each subsequent treatment both for knee and hip</span></p>
<p style="top:344.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">OA. In addition, Centeno et al. [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">39</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] suggested that patients</span></p>
<p style="top:357.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">receiving a BMAC injection with a higher concentration of</span></p>
<p style="top:369.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cells reported a better pain outcome in comparison with the</span></p>
<p style="top:382.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">lower dose group. The role of OA severity was underlined in</span></p>
<p style="top:394.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">two studies [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">41</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 43</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] showing better clinical results after intra-</span></p>
<p style="top:407.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">articular BMAC injections in patients with moderate OA com-</span></p>
<p style="top:419.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">pared with those with severe OA (Kellgren-Lawrence grade</span></p>
<p style="top:431.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">4). Finally, the possibility to improve the results by combining</span></p>
<p style="top:444.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">different products was investigated in two comparative studies</span></p>
<p style="top:456.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">[</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">40</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 47</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], where the combination of BMAC and adipose tissue</span></p>
<p style="top:469.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">did not prove superiority with respect to BMAC alone.</span></p>
<p style="top:481.7pt;left:317.5pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Safety was documented by all studies, with no severe</span></p>
<p style="top:494.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">adverse events related to the injective procedures. The most</span></p>
<p style="top:506.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">common reported adverse effects were temporary pain or</span></p>
<p style="top:519.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">joint swelling during the first weeks after BMAC injection,</span></p>
<p style="top:531.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">followed by grinding, popping, and snapping sensations</span></p>
<p style="top:544.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">with specific movements. Centeno et al. [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">47</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] documented</span></p>
<p style="top:556.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">in a multi-center safety analysis a 12% rate of adverse</span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">events in a large group of OA patients treated with intra-</span></p>
<p style="top:581.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">articular injections of BMAC. In particular, patients receiv-</span></p>
<p style="top:593.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ing BMAC injections alone reported fewer adverse events</span></p>
<p style="top:606.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">with respect to patients treated with intra-articular com-</span></p>
<p style="top:618.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">bined injections (e.g., BMAC plus adipose tissue). The</span></p>
<p style="top:631.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">same group also reported in another study [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">35</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] one patient</span></p>
<p style="top:643.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">with a persistent popliteal fossa fluid accumulation after the</span></p>
<p style="top:656.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">injection procedure, which was aspirated and resolved.</span></p>
<p style="top:668.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Finally, Hernigou et al. [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">36</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] reported a higher safety rate</span></p>
<p style="top:681.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">in patients treated with knee subchondral BMAC injections</span></p>
<p style="top:693.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">compared with patients who underwent total knee</span></p>
<p style="top:705.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">arthroplasty.</span></p>
<p style="top:33.5pt;left:532.3pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">529</span></p>
<p style="top:33.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">International Orthopaedics (SICOT) (2021) 45:525&#x2013;538</span></p>


<p style="top:707.1pt;left:53.4pt;line-height:8.5pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:8.5pt;color:#131313">Table 2</span></p>
<p style="top:672.1pt;left:53.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Clinical study characteristics</span></p>
<p style="top:707.1pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Author and</span></p>
<p style="top:707.1pt;left:82.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">year</span></p>
<p style="top:636.9pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Study design</span></p>
<p style="top:561.2pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Joint</span></p>
<p style="top:510.4pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Treatment</span></p>
<p style="top:421.0pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Harvest</span></p>
<p style="top:421.0pt;left:82.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">site</span></p>
<p style="top:375.2pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Bone</span></p>
<p style="top:375.2pt;left:82.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">marrow concentration</span></p>
<p style="top:375.2pt;left:92.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">and injected amount</span></p>
<p style="top:288.8pt;left:71.7pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Patient,</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> n</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> (M/F)</span></p>
<p style="top:288.8pt;left:82.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Age, mean</span></p>
<p style="top:288.8pt;left:92.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(SD or range)</span></p>
<p style="top:213.1pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">F-up</span></p>
<p style="top:184.6pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Results and adverse events</span></p>
<p style="top:71.1pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">mCMS</span></p>
<p style="top:706.9pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Anz AW et al.</span></p>
<p style="top:698.4pt;left:121.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2020 [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#0000ff">31</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">]</span></p>
<p style="top:636.7pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Unblinded RCT</span></p>
<p style="top:561.0pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Knee</span></p>
<p style="top:510.1pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC vs. LR-PRP</span></p>
<p style="top:501.6pt;left:121.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Single IA injection</span></p>
<p style="top:420.7pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">PSIS</span></p>
<p style="top:374.9pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Dual-Spin</span></p>
<p style="top:366.4pt;left:121.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">protocol/disposable</span></p>
<p style="top:366.4pt;left:130.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">PureBMc - EmCyte</span></p>
<p style="top:374.9pt;left:139.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">(Fort Myers, FL, USA)</span></p>
<p style="top:374.9pt;left:148.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">7 ml of BMAC</span></p>
<p style="top:277.6pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC group</span></p>
<p style="top:271.7pt;left:121.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">45 (27/18)</span></p>
<p style="top:276.6pt;left:130.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">56 years (11)</span></p>
<p style="top:279.3pt;left:139.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">LR-PRP group</span></p>
<p style="top:271.7pt;left:148.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">41 (22/19)</span></p>
<p style="top:276.6pt;left:158.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">52 years (12)</span></p>
<p style="top:212.8pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">12 m</span></p>
<p style="top:184.3pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">All scores for both PRP and</span></p>
<p style="top:175.8pt;left:121.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC groups significantly</span></p>
<p style="top:175.8pt;left:130.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">improved up to 12 months,</span></p>
<p style="top:175.8pt;left:139.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">with no difference between</span></p>
<p style="top:173.7pt;left:148.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">PRP and BMAC at any time</span></p>
<p style="top:175.8pt;left:158.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">point. No adverse events</span></p>
<p style="top:175.8pt;left:167.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">were reported.</span></p>
<p style="top:70.9pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">60</span></p>
<p style="top:706.9pt;left:176.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Mautner K et al.</span></p>
<p style="top:698.4pt;left:185.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2019 [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#0000ff">32</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">]</span></p>
<p style="top:636.7pt;left:176.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Retrospective</span></p>
<p style="top:628.2pt;left:185.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">comparative</span></p>
<p style="top:628.2pt;left:195.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">study</span></p>
<p style="top:561.0pt;left:176.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Knee</span></p>
<p style="top:510.1pt;left:176.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC vs. MFAT</span></p>
<p style="top:510.1pt;left:185.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Single IA injection</span></p>
<p style="top:420.7pt;left:176.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">PSIS</span></p>
<p style="top:374.9pt;left:176.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">EmCyte centrifuge</span></p>
<p style="top:374.9pt;left:185.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">(Fort Myers, FL, USA)</span></p>
<p style="top:374.9pt;left:195.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">8 ml of BMAC</span></p>
<p style="top:277.6pt;left:176.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC group</span></p>
<p style="top:271.7pt;left:185.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">41 (24/17)</span></p>
<p style="top:274.5pt;left:195.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">59 years (1)</span></p>
<p style="top:276.8pt;left:204.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">MFAT group</span></p>
<p style="top:271.7pt;left:213.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">35 (12/23)</span></p>
<p style="top:276.6pt;left:223.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">63 years (11)</span></p>
<p style="top:212.8pt;left:176.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">22 m</span></p>
<p style="top:184.3pt;left:176.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">There were significant</span></p>
<p style="top:175.8pt;left:185.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">improvements in pain and</span></p>
<p style="top:175.8pt;left:195.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">function with both</span></p>
<p style="top:175.8pt;left:204.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">treatments, without a</span></p>
<p style="top:175.8pt;left:213.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">significant difference</span></p>
<p style="top:175.8pt;left:223.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">between the two groups.</span></p>
<p style="top:184.3pt;left:232.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">No adverse events were</span></p>
<p style="top:175.8pt;left:241.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">reported.</span></p>
<p style="top:70.9pt;left:176.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">35</span></p>
<p style="top:706.9pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Shapiro SA et al.</span></p>
<p style="top:698.4pt;left:260.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2019 [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#0000ff">33</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">]</span></p>
<p style="top:636.7pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Blinded RCT</span></p>
<p style="top:628.2pt;left:260.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">(self-controlled)</span></p>
<p style="top:561.0pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Knee</span></p>
<p style="top:552.5pt;left:260.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">(bilateral)</span></p>
<p style="top:510.1pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC vs. saline</span></p>
<p style="top:510.1pt;left:260.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Single IA injection</span></p>
<p style="top:420.7pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">PSIS</span></p>
<p style="top:374.9pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Magellan Autologous</span></p>
<p style="top:366.4pt;left:260.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Platelet Separator</span></p>
<p style="top:366.4pt;left:269.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">System</span></p>
<p style="top:366.4pt;left:278.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">(Arteriocyte, USA)</span></p>
<p style="top:374.9pt;left:287.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">5 ml of BMAC +</span></p>
<p style="top:366.4pt;left:297.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">10 ml</span></p>
<p style="top:366.4pt;left:306.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">of PPP</span></p>
<p style="top:374.9pt;left:315.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC product</span></p>
<p style="top:366.4pt;left:324.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">contained a median</span></p>
<p style="top:366.4pt;left:334.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">of 56% MNCs</span></p>
<p style="top:366.4pt;left:339.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">(150 &#xd7; 10</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:6.2pt;color:#131313">6</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313"> WBC,</span></p>
<p style="top:366.4pt;left:351.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">80 &#xd7; 10</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:6.2pt;color:#131313">6</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">MNC,</span></p>
<p style="top:366.4pt;left:360.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">4.4 &#xd7; 10</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:6.2pt;color:#131313">6</span></p>
<p style="top:366.4pt;left:371.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">hematopoietic stem</span></p>
<p style="top:366.4pt;left:380.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">cells, and 34,000</span></p>
<p style="top:366.4pt;left:389.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">MSCs)</span></p>
<p style="top:275.5pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Bilateral OA</span></p>
<p style="top:262.6pt;left:260.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">patients</span></p>
<p style="top:269.5pt;left:269.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">25 (7/18)</span></p>
<p style="top:283.0pt;left:278.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">60 years (42</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.8pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">68)</span></p>
<p style="top:212.8pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">12 m</span></p>
<p style="top:184.3pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">No difference between BMAC-</span></p>
<p style="top:175.8pt;left:260.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">and saline-treated knees in</span></p>
<p style="top:175.8pt;left:269.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">patients with bilateral knee</span></p>
<p style="top:175.8pt;left:278.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">OA.</span></p>
<p style="top:184.3pt;left:287.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">No adverse events were</span></p>
<p style="top:175.8pt;left:297.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">encountered.</span></p>
<p style="top:70.9pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">57</span></p>
<p style="top:706.9pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Subasi T et al.</span></p>
<p style="top:698.4pt;left:408.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2019 [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#0000ff">34</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">]</span></p>
<p style="top:636.7pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Prospective</span></p>
<p style="top:628.2pt;left:408.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">case series</span></p>
<p style="top:561.0pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Knee</span></p>
<p style="top:510.1pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC</span></p>
<p style="top:510.1pt;left:408.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Single IA injection</span></p>
<p style="top:501.6pt;left:417.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">(followed 1 month</span></p>
<p style="top:501.6pt;left:426.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">later by a PRP</span></p>
<p style="top:501.6pt;left:436.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">injection)</span></p>
<p style="top:420.7pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">PSIS</span></p>
<p style="top:374.9pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">MC kitTM (nFinders,</span></p>
<p style="top:366.4pt;left:408.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Seoul, Korea)</span></p>
<p style="top:374.9pt;left:417.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">4 ml of BMAC</span></p>
<p style="top:265.2pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">3 (0/3)</span></p>
<p style="top:276.6pt;left:408.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">58 years (10)</span></p>
<p style="top:212.8pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2 m</span></p>
<p style="top:184.3pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">IA BMAC and PRP treatments</span></p>
<p style="top:175.8pt;left:408.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">may have positive effects on</span></p>
<p style="top:175.8pt;left:417.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">pain, functional status, and</span></p>
<p style="top:175.8pt;left:426.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">quality of life in patients with</span></p>
<p style="top:175.8pt;left:436.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">knee OA. No side effects or</span></p>
<p style="top:175.8pt;left:445.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">tractable pain were detected.</span></p>
<p style="top:70.9pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">27</span></p>
<p style="top:706.9pt;left:454.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Centeno C et al.</span></p>
<p style="top:698.4pt;left:463.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2018 [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#0000ff">35</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">]</span></p>
<p style="top:636.7pt;left:454.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Unblinded RCT</span></p>
<p style="top:561.0pt;left:454.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Knee</span></p>
<p style="top:510.1pt;left:454.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC + platelet</span></p>
<p style="top:501.6pt;left:463.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">products vs. exercise</span></p>
<p style="top:501.6pt;left:473.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">therapy (pre-injection</span></p>
<p style="top:501.6pt;left:482.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">of dextrose,</span></p>
<p style="top:501.6pt;left:491.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">post-injection of PRP,</span></p>
<p style="top:501.6pt;left:500.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">hydrocortisone, and</span></p>
<p style="top:501.6pt;left:510.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">doxycycline after 2</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.8pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">-</span></p>
<p style="top:501.6pt;left:519.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">4 days)</span></p>
<p style="top:510.1pt;left:528.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Single IA injection</span></p>
<p style="top:420.7pt;left:454.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">PSIS</span></p>
<p style="top:374.9pt;left:454.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">The aspirate was</span></p>
<p style="top:366.4pt;left:463.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">processed in a sterile</span></p>
<p style="top:366.4pt;left:473.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">ISO-7 class clean</span></p>
<p style="top:366.4pt;left:482.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">room</span></p>
<p style="top:374.9pt;left:491.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">5</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.8pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">7 ml injectate</span></p>
<p style="top:366.4pt;left:500.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">solution</span></p>
<p style="top:374.9pt;left:510.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">(75% of BMAC)</span></p>
<p style="top:277.6pt;left:454.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC group</span></p>
<p style="top:258.0pt;left:463.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">26</span></p>
<p style="top:274.5pt;left:473.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">54 years (9)</span></p>
<p style="top:279.4pt;left:482.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Exercise group</span></p>
<p style="top:258.0pt;left:491.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">22</span></p>
<p style="top:274.5pt;left:500.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">57 years (8)</span></p>
<p style="top:212.8pt;left:454.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">24 m</span></p>
<p style="top:184.3pt;left:454.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">The use of BMAC with platelet</span></p>
<p style="top:175.8pt;left:463.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">products yielded better</span></p>
<p style="top:175.8pt;left:473.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">results than exercise therapy.</span></p>
<p style="top:175.8pt;left:482.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">No</span></p>
<p style="top:175.8pt;left:491.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">serious adverse events were</span></p>
<p style="top:175.8pt;left:500.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">identified. One patient</span></p>
<p style="top:175.8pt;left:510.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">reported a persistent popliteal</span></p>
<p style="top:175.8pt;left:519.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">fossa fluid accumulation,</span></p>
<p style="top:175.8pt;left:528.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">which was aspirated.</span></p>
<p style="top:70.9pt;left:454.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">55</span></p>
<p style="top:33.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">530</span></p>
<p style="top:33.5pt;left:369.1pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">International Orthopaedics (SICOT) (2021) 45:525&#x2013;538</span></p>


<p style="top:707.1pt;left:53.5pt;line-height:8.5pt"><span style="font-family:XmhmcyAdvTTb8864ccf.B,serif;font-size:8.5pt;color:#131313">Table 2</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> (continued)</span></p>
<p style="top:707.1pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Author and</span></p>
<p style="top:707.1pt;left:82.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">year</span></p>
<p style="top:636.9pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Study design</span></p>
<p style="top:561.2pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Joint</span></p>
<p style="top:510.5pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Treatment</span></p>
<p style="top:421.0pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Harvest</span></p>
<p style="top:421.0pt;left:82.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">site</span></p>
<p style="top:375.2pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Bone</span></p>
<p style="top:375.2pt;left:82.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">marrow concentration</span></p>
<p style="top:375.2pt;left:92.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">and injected amount</span></p>
<p style="top:288.8pt;left:71.7pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Patient,</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> n</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> (M/F)</span></p>
<p style="top:288.8pt;left:82.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Age, mean</span></p>
<p style="top:280.3pt;left:92.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(SD or range)</span></p>
<p style="top:213.1pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">F-up</span></p>
<p style="top:184.6pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Results and adverse events</span></p>
<p style="top:71.1pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">mCMS</span></p>
<p style="top:706.9pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Hernigou P et al.</span></p>
<p style="top:698.4pt;left:121.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2018 [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#0000ff">36</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">]</span></p>
<p style="top:636.7pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Unblinded RCT</span></p>
<p style="top:561.0pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Knee</span></p>
<p style="top:510.2pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC vs. TKA</span></p>
<p style="top:510.2pt;left:121.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Single subchondral</span></p>
<p style="top:501.6pt;left:130.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">injection</span></p>
<p style="top:420.7pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">ASIS</span></p>
<p style="top:374.9pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">40 ml of BMAC in the</span></p>
<p style="top:366.4pt;left:121.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">subchondral medial</span></p>
<p style="top:366.4pt;left:130.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">and lateral</span></p>
<p style="top:366.4pt;left:139.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">femorotibial</span></p>
<p style="top:366.4pt;left:148.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">compartments.</span></p>
<p style="top:366.4pt;left:158.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC contains an</span></p>
<p style="top:366.4pt;left:167.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">average of 6500</span></p>
<p style="top:366.4pt;left:176.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">MSCs/ml</span></p>
<p style="top:271.7pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">30 (12/18)</span></p>
<p style="top:283.0pt;left:121.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">28 years (18</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.8pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">41)</span></p>
<p style="top:212.8pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">144 m Subchondral BMAC was an</span></p>
<p style="top:175.8pt;left:121.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">effective procedure for</span></p>
<p style="top:175.8pt;left:130.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">treating young patients with</span></p>
<p style="top:175.8pt;left:139.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">knee OA following</span></p>
<p style="top:175.8pt;left:148.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">secondary osteonecrosis.</span></p>
<p style="top:175.8pt;left:158.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">During the postoperative</span></p>
<p style="top:175.8pt;left:167.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">period, the number of</span></p>
<p style="top:175.8pt;left:176.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">adverse events was higher in</span></p>
<p style="top:175.8pt;left:185.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">the TKA group.</span></p>
<p style="top:70.9pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">67</span></p>
<p style="top:706.9pt;left:195.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Shaw B et al.</span></p>
<p style="top:698.4pt;left:204.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2018 [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#0000ff">37</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">]</span></p>
<p style="top:636.7pt;left:195.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Retrospective</span></p>
<p style="top:628.2pt;left:204.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">case series</span></p>
<p style="top:561.0pt;left:195.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Knee</span></p>
<p style="top:510.2pt;left:195.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC</span></p>
<p style="top:510.2pt;left:204.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">4 IA injections</span></p>
<p style="top:501.6pt;left:213.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">(1 every 2 weeks)</span></p>
<p style="top:420.7pt;left:195.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">PSIS</span></p>
<p style="top:374.9pt;left:195.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">The BMAC was spun</span></p>
<p style="top:366.4pt;left:204.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">in a centrifuge, and</span></p>
<p style="top:366.4pt;left:213.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">the upper portion</span></p>
<p style="top:366.4pt;left:223.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">without visible red</span></p>
<p style="top:366.4pt;left:232.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">cells was isolated</span></p>
<p style="top:366.4pt;left:241.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">from the centrifuged</span></p>
<p style="top:366.4pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC.</span></p>
<p style="top:374.9pt;left:260.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">5 ml of BMAC + 1 ml</span></p>
<p style="top:366.4pt;left:269.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">of ropivacaine</span></p>
<p style="top:269.5pt;left:195.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">15 (5/10)</span></p>
<p style="top:274.5pt;left:204.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">68 years (8)</span></p>
<p style="top:212.8pt;left:195.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">3 m</span></p>
<p style="top:184.3pt;left:195.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Outcomes at the final follow-up</span></p>
<p style="top:175.8pt;left:204.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">after the fourth treatment</span></p>
<p style="top:175.8pt;left:213.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">were statistically significant</span></p>
<p style="top:175.8pt;left:223.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">compared with outcomes at</span></p>
<p style="top:175.8pt;left:232.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">baseline. No serious adverse</span></p>
<p style="top:175.8pt;left:241.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">events were reported.</span></p>
<p style="top:70.9pt;left:195.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">24</span></p>
<p style="top:706.9pt;left:278.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Themistocleous</span></p>
<p style="top:698.4pt;left:287.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">GS et al. 2018</span></p>
<p style="top:698.4pt;left:297.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">[</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#0000ff">38</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">]</span></p>
<p style="top:636.7pt;left:278.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Retrospective</span></p>
<p style="top:628.2pt;left:287.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">case series</span></p>
<p style="top:561.0pt;left:278.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Knee</span></p>
<p style="top:510.2pt;left:278.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC</span></p>
<p style="top:510.2pt;left:287.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Single IA injection</span></p>
<p style="top:420.7pt;left:278.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">ASIS</span></p>
<p style="top:374.9pt;left:278.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Single-spin</span></p>
<p style="top:366.4pt;left:287.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">centrifugation</span></p>
<p style="top:366.4pt;left:297.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">technique (Hettich&#xae;</span></p>
<p style="top:366.4pt;left:306.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Rotofix 32A</span></p>
<p style="top:366.4pt;left:315.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">centrifuge)</span></p>
<p style="top:374.9pt;left:324.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">10 ml of BMAC</span></p>
<p style="top:273.8pt;left:278.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">121 (35/86)</span></p>
<p style="top:283.0pt;left:287.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">70 years (50</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.8pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">85)</span></p>
<p style="top:212.8pt;left:278.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">11 m</span></p>
<p style="top:184.3pt;left:278.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC was a safe and reliable</span></p>
<p style="top:175.8pt;left:287.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">procedure that resulted in</span></p>
<p style="top:175.8pt;left:297.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">clinical improvement in</span></p>
<p style="top:175.8pt;left:306.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">patients with grades 3 and</span></p>
<p style="top:175.8pt;left:315.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">4 knee OA. There were no</span></p>
<p style="top:175.8pt;left:324.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">adverse events or</span></p>
<p style="top:175.8pt;left:334.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">complications.</span></p>
<p style="top:70.9pt;left:278.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">41</span></p>
<p style="top:706.9pt;left:343.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Centeno C et al.</span></p>
<p style="top:698.4pt;left:352.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2015 [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#0000ff">39</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">]</span></p>
<p style="top:636.7pt;left:343.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Retrospective</span></p>
<p style="top:628.2pt;left:352.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">comparative</span></p>
<p style="top:628.2pt;left:362.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">study</span></p>
<p style="top:561.0pt;left:343.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Knee</span></p>
<p style="top:510.2pt;left:343.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC (higher cell</span></p>
<p style="top:501.6pt;left:352.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">count) + platelet</span></p>
<p style="top:501.6pt;left:362.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">products vs. BMAC</span></p>
<p style="top:501.6pt;left:371.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">(lower cell count) +</span></p>
<p style="top:501.6pt;left:380.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">platelet products</span></p>
<p style="top:510.2pt;left:389.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Single IA injection</span></p>
<p style="top:420.7pt;left:343.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">PSIS</span></p>
<p style="top:374.9pt;left:343.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">The aspirate was</span></p>
<p style="top:366.4pt;left:352.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">processed in a sterile</span></p>
<p style="top:366.4pt;left:362.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">ISO-7 class clean</span></p>
<p style="top:366.4pt;left:371.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">room.</span></p>
<p style="top:374.9pt;left:380.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Higher cell count group</span></p>
<p style="top:374.9pt;left:389.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC: &gt; 4 &#xd7; 108 cells</span></p>
<p style="top:374.9pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Lower cell count group</span></p>
<p style="top:374.9pt;left:407.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC:</span><span style="font-family:XnwwwtAdvTT3713a231+22,serif;font-size:8.8pt;color:#131313"> &#x2264;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313"> 4 &#xd7; 108 cells</span></p>
<p style="top:283.4pt;left:343.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Higher cell count</span></p>
<p style="top:260.2pt;left:352.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">224</span></p>
<p style="top:276.6pt;left:362.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">54 years (13)</span></p>
<p style="top:282.7pt;left:371.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Lower cell count</span></p>
<p style="top:260.2pt;left:380.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">185</span></p>
<p style="top:276.6pt;left:389.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">50 years (16)</span></p>
<p style="top:212.8pt;left:343.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">12 m</span></p>
<p style="top:184.3pt;left:343.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Patients receiving a higher</span></p>
<p style="top:175.8pt;left:352.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">concentration of cells</span></p>
<p style="top:175.8pt;left:362.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">reported</span></p>
<p style="top:175.8pt;left:371.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">a better pain outcome in</span></p>
<p style="top:175.8pt;left:380.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">comparison with the lower</span></p>
<p style="top:175.8pt;left:389.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">dose group.</span></p>
<p style="top:184.3pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">No adverse events were</span></p>
<p style="top:175.8pt;left:408.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">reported.</span></p>
<p style="top:70.9pt;left:343.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">28</span></p>
<p style="top:706.9pt;left:417.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Centeno C et al.</span></p>
<p style="top:698.4pt;left:426.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2014 [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#0000ff">43</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">]</span></p>
<p style="top:636.7pt;left:417.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Retrospective</span></p>
<p style="top:628.2pt;left:426.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">comparative</span></p>
<p style="top:628.2pt;left:436.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">study</span></p>
<p style="top:561.0pt;left:417.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Knee</span></p>
<p style="top:510.2pt;left:417.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC + platelet</span></p>
<p style="top:501.6pt;left:426.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">products vs. BMAC +</span></p>
<p style="top:501.6pt;left:436.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">platelet products +</span></p>
<p style="top:501.6pt;left:445.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">adipose</span></p>
<p style="top:501.6pt;left:454.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">graft (pre-injection of</span></p>
<p style="top:501.6pt;left:463.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">dextrose)</span></p>
<p style="top:510.2pt;left:473.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Single IA injection</span></p>
<p style="top:420.7pt;left:417.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">PSIS</span></p>
<p style="top:374.9pt;left:417.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">The aspirate was</span></p>
<p style="top:364.5pt;left:426.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">processed in a sterile</span></p>
<p style="top:366.4pt;left:436.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">ISO-7 class clean</span></p>
<p style="top:366.4pt;left:445.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">room.</span></p>
<p style="top:374.9pt;left:454.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">1</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.8pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">3 ml BMAC injected</span></p>
<p style="top:366.4pt;left:463.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">intra-articularly and</span></p>
<p style="top:366.4pt;left:473.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">in painful or dam-</span></p>
<p style="top:366.4pt;left:482.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">aged structures</span></p>
<p style="top:269.0pt;left:417.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Group A</span></p>
<p style="top:260.2pt;left:426.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">518</span></p>
<p style="top:276.6pt;left:436.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">54 years (14)</span></p>
<p style="top:268.7pt;left:445.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Group B</span></p>
<p style="top:260.2pt;left:454.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">163</span></p>
<p style="top:276.6pt;left:463.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">60 years (10)</span></p>
<p style="top:212.8pt;left:417.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">12 m</span></p>
<p style="top:184.3pt;left:417.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Although improvements were</span></p>
<p style="top:175.8pt;left:426.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">statistically significant, the</span></p>
<p style="top:175.8pt;left:436.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">differences between the</span></p>
<p style="top:175.8pt;left:445.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">groups were not. No adverse</span></p>
<p style="top:175.8pt;left:454.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">events secondary to the</span></p>
<p style="top:175.8pt;left:463.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">procedure</span></p>
<p style="top:175.8pt;left:473.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">were reported.</span></p>
<p style="top:70.9pt;left:417.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">23</span></p>
<p style="top:561.0pt;left:491.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Knee</span></p>
<p style="top:510.2pt;left:491.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC + adipose tissue</span></p>
<p style="top:271.7pt;left:491.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">41 (17/24)</span></p>
<p style="top:212.8pt;left:491.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">12 m</span></p>
<p style="top:70.9pt;left:491.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">44</span></p>
<p style="top:33.5pt;left:532.3pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">531</span></p>
<p style="top:33.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">International Orthopaedics (SICOT) (2021) 45:525&#x2013;538</span></p>


<p style="top:707.1pt;left:53.5pt;line-height:8.5pt"><span style="font-family:XmhmcyAdvTTb8864ccf.B,serif;font-size:8.5pt;color:#131313">Table 2</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> (continued)</span></p>
<p style="top:707.1pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Author and</span></p>
<p style="top:707.1pt;left:82.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">year</span></p>
<p style="top:636.9pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Study design</span></p>
<p style="top:561.2pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Joint</span></p>
<p style="top:510.5pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Treatment</span></p>
<p style="top:421.0pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Harvest</span></p>
<p style="top:421.0pt;left:82.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">site</span></p>
<p style="top:375.2pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Bone</span></p>
<p style="top:375.2pt;left:82.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">marrow concentration</span></p>
<p style="top:375.2pt;left:92.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">and injected amount</span></p>
<p style="top:288.8pt;left:71.7pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Patient,</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> n</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> (M/F)</span></p>
<p style="top:288.8pt;left:82.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Age, mean</span></p>
<p style="top:280.3pt;left:92.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(SD or range)</span></p>
<p style="top:213.1pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">F-up</span></p>
<p style="top:184.6pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Results and adverse events</span></p>
<p style="top:71.1pt;left:72.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">mCMS</span></p>
<p style="top:706.9pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Kim JD et al.</span></p>
<p style="top:698.4pt;left:121.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2014</span></p>
<p style="top:698.4pt;left:130.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">[</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#0000ff">41</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">]</span></p>
<p style="top:636.7pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Prospective</span></p>
<p style="top:628.2pt;left:121.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">case series</span></p>
<p style="top:510.2pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Associated surgery</span></p>
<p style="top:501.6pt;left:121.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">in 16% of patients</span></p>
<p style="top:510.2pt;left:130.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Single IA injection</span></p>
<p style="top:420.7pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">ASIS or</span></p>
<p style="top:412.2pt;left:121.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">PSIS</span></p>
<p style="top:374.9pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">SmartPReP2 BMAC2</span></p>
<p style="top:366.4pt;left:121.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">kits (Harvest</span></p>
<p style="top:366.4pt;left:130.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Technology, USA)</span></p>
<p style="top:374.9pt;left:139.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">7 ml BMAC + 10 ml</span></p>
<p style="top:366.4pt;left:148.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">ADSCs</span></p>
<p style="top:283.0pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">61 years (53</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.8pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">80)</span></p>
<p style="top:184.3pt;left:111.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC injection significantly</span></p>
<p style="top:175.8pt;left:121.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">improved both knee pain and</span></p>
<p style="top:175.8pt;left:130.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">function in the patients with</span></p>
<p style="top:175.8pt;left:139.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">knee OA.</span></p>
<p style="top:184.3pt;left:148.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">No adverse events were</span></p>
<p style="top:175.8pt;left:158.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">reported.</span></p>
<p style="top:706.9pt;left:167.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Darrow M et al.</span></p>
<p style="top:698.4pt;left:176.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2018 [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#0000ff">42</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">]</span></p>
<p style="top:636.7pt;left:167.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Retrospective</span></p>
<p style="top:628.2pt;left:176.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">case series</span></p>
<p style="top:561.0pt;left:167.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Hip</span></p>
<p style="top:510.2pt;left:167.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC 4 intra-articular</span></p>
<p style="top:501.6pt;left:176.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">injections</span></p>
<p style="top:501.6pt;left:185.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">(1 every 2 weeks)</span></p>
<p style="top:420.7pt;left:167.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">PSIS</span></p>
<p style="top:374.9pt;left:167.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">The BMAC was spun</span></p>
<p style="top:366.4pt;left:176.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">in a centrifuge, and</span></p>
<p style="top:366.4pt;left:185.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">the upper portion</span></p>
<p style="top:366.4pt;left:195.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">without visible red</span></p>
<p style="top:366.4pt;left:204.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">cells was isolated</span></p>
<p style="top:366.4pt;left:213.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">from the centrifuged</span></p>
<p style="top:366.4pt;left:223.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC.</span></p>
<p style="top:374.9pt;left:232.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">5 ml of BMAC + 1 ml</span></p>
<p style="top:366.4pt;left:241.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">of ropivacaine</span></p>
<p style="top:265.2pt;left:167.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">4 (3/1)</span></p>
<p style="top:276.6pt;left:176.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">67 years (10)</span></p>
<p style="top:212.8pt;left:167.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">4 m</span></p>
<p style="top:184.3pt;left:167.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">All patients experienced</span></p>
<p style="top:175.8pt;left:176.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">decreased pain and improved</span></p>
<p style="top:175.8pt;left:185.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">functionality compared with</span></p>
<p style="top:175.8pt;left:195.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">baseline.</span></p>
<p style="top:184.3pt;left:204.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">No adverse events were</span></p>
<p style="top:175.8pt;left:213.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">reported.</span></p>
<p style="top:70.9pt;left:167.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">23</span></p>
<p style="top:706.9pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Centeno C et al.</span></p>
<p style="top:698.4pt;left:260.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2014 [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#0000ff">43</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">]</span></p>
<p style="top:636.7pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Retrospective</span></p>
<p style="top:628.2pt;left:260.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">case series</span></p>
<p style="top:561.0pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Hip</span></p>
<p style="top:510.2pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC + platelet</span></p>
<p style="top:501.6pt;left:260.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">products</span></p>
<p style="top:501.6pt;left:269.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">(pre-injection of</span></p>
<p style="top:501.6pt;left:278.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">dextrose)</span></p>
<p style="top:510.2pt;left:287.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Single IA injection</span></p>
<p style="top:420.7pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">PSIS</span></p>
<p style="top:374.9pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">The aspirate was</span></p>
<p style="top:366.4pt;left:260.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">processed in a sterile</span></p>
<p style="top:366.4pt;left:269.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">ISO-7 class clean</span></p>
<p style="top:366.4pt;left:278.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">room.</span></p>
<p style="top:374.9pt;left:287.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">1</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.8pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">4 ml of BMAC +</span></p>
<p style="top:366.4pt;left:297.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2 ml of PRP + PL</span></p>
<p style="top:275.9pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">216 (124/92)</span></p>
<p style="top:276.6pt;left:260.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">57 years (11)</span></p>
<p style="top:212.8pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">9 m</span></p>
<p style="top:184.3pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC injections for hip OA</span></p>
<p style="top:175.8pt;left:260.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">demonstrated encouraging</span></p>
<p style="top:175.8pt;left:269.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">results for improved</span></p>
<p style="top:175.8pt;left:278.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">outcomes with no significant</span></p>
<p style="top:175.8pt;left:287.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">complications.</span></p>
<p style="top:184.3pt;left:297.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">There were no severe or</span></p>
<p style="top:175.8pt;left:306.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">serious adverse events.</span></p>
<p style="top:70.9pt;left:250.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">26</span></p>
<p style="top:706.9pt;left:315.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Darrow M et al.</span></p>
<p style="top:698.4pt;left:324.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2019 [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#0000ff">44</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">]</span></p>
<p style="top:636.7pt;left:315.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Retrospective</span></p>
<p style="top:628.2pt;left:324.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">comparative</span></p>
<p style="top:628.2pt;left:334.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">study</span></p>
<p style="top:561.0pt;left:315.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Shoulder</span></p>
<p style="top:510.2pt;left:315.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC vs. WBM 1</span></p>
<p style="top:501.6pt;left:324.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">or 2 IA injections</span></p>
<p style="top:420.7pt;left:315.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">PSIS</span></p>
<p style="top:374.9pt;left:315.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">The BMAC was spun</span></p>
<p style="top:366.4pt;left:324.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">in a centrifuge, and</span></p>
<p style="top:366.4pt;left:334.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">the upper portion</span></p>
<p style="top:366.4pt;left:343.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">without visible red</span></p>
<p style="top:366.4pt;left:352.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">cells was isolated</span></p>
<p style="top:366.4pt;left:362.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">from the centrifuged</span></p>
<p style="top:366.4pt;left:371.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC.</span></p>
<p style="top:374.9pt;left:380.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">5 ml of BMAC + 1 ml</span></p>
<p style="top:366.4pt;left:389.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">of ropivacaine</span></p>
<p style="top:258.0pt;left:315.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">32</span></p>
<p style="top:212.8pt;left:315.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">8 m</span></p>
<p style="top:184.3pt;left:315.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Injective BMAC or WBM</span></p>
<p style="top:175.8pt;left:324.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">treatment in patients with</span></p>
<p style="top:175.8pt;left:334.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">shoulder OA significantly</span></p>
<p style="top:175.8pt;left:343.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">improved resting pain, active</span></p>
<p style="top:175.8pt;left:352.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">pain, and functionality score,</span></p>
<p style="top:175.8pt;left:362.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">with greater results in group</span></p>
<p style="top:175.8pt;left:371.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">with 2 injections.</span></p>
<p style="top:184.3pt;left:380.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">No adverse events were</span></p>
<p style="top:175.8pt;left:389.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">reported.</span></p>
<p style="top:70.9pt;left:315.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">24</span></p>
<p style="top:706.9pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Centeno C et al.</span></p>
<p style="top:698.4pt;left:408.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2015 [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#0000ff">45</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">]</span></p>
<p style="top:636.7pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Retrospective</span></p>
<p style="top:628.2pt;left:408.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">case series</span></p>
<p style="top:561.0pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Shoulder</span></p>
<p style="top:510.2pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC + platelet</span></p>
<p style="top:501.6pt;left:408.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">products</span></p>
<p style="top:501.6pt;left:417.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">(pre-injection</span></p>
<p style="top:501.6pt;left:426.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">of dextrose)</span></p>
<p style="top:510.2pt;left:436.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Single IA injection</span></p>
<p style="top:420.7pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">PSIS</span></p>
<p style="top:374.9pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">The aspirate was</span></p>
<p style="top:366.4pt;left:408.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">processed in a sterile</span></p>
<p style="top:366.4pt;left:417.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">ISO-7 class clean</span></p>
<p style="top:366.4pt;left:426.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">room.</span></p>
<p style="top:374.9pt;left:436.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">1</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.8pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">4 ml of BMAC +</span></p>
<p style="top:366.4pt;left:445.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">1 ml of PRP + 1 ml</span></p>
<p style="top:366.4pt;left:454.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">of PLCell count:</span></p>
<p style="top:366.4pt;left:462.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">3.85 &#xd7; 10</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:6.2pt;color:#131313">8</span></p>
<p style="top:269.5pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">34 (27/7)</span></p>
<p style="top:276.6pt;left:408.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">52 years (17)</span></p>
<p style="top:212.8pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">11 m</span></p>
<p style="top:184.3pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">The use of BMAC to treat</span></p>
<p style="top:175.8pt;left:408.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">shoulder OA was effective at</span></p>
<p style="top:175.8pt;left:417.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">improving pain and function.</span></p>
<p style="top:184.3pt;left:426.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">No serious adverse events were</span></p>
<p style="top:175.8pt;left:436.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">reported.</span></p>
<p style="top:70.9pt;left:399.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">29</span></p>
<p style="top:706.9pt;left:473.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Rodriguez-Fontan</span></p>
<p style="top:698.4pt;left:482.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">F et al. 2018</span></p>
<p style="top:698.4pt;left:491.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">[</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#0000ff">46</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">]</span></p>
<p style="top:636.7pt;left:473.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Prospective</span></p>
<p style="top:628.2pt;left:482.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">case series</span></p>
<p style="top:561.0pt;left:473.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Knee</span></p>
<p style="top:561.0pt;left:482.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Hip</span></p>
<p style="top:510.2pt;left:473.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC</span></p>
<p style="top:510.2pt;left:482.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Single IA injection</span></p>
<p style="top:420.7pt;left:473.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">ASIS</span></p>
<p style="top:375.0pt;left:473.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BioCUE Platelet</span></p>
<p style="top:366.4pt;left:482.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Concentration</span></p>
<p style="top:366.4pt;left:491.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">System (Zimmer</span></p>
<p style="top:366.4pt;left:501.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Biomet, Warsaw)</span></p>
<p style="top:374.9pt;left:510.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">12 ml of BMAC</span></p>
<p style="top:269.5pt;left:473.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">19 (3/16)</span></p>
<p style="top:276.6pt;left:482.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">58 years (13)</span></p>
<p style="top:212.8pt;left:473.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">24 m</span></p>
<p style="top:184.3pt;left:473.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">IA injections of BMAC for the</span></p>
<p style="top:175.8pt;left:482.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">treatment of early knee or hip</span></p>
<p style="top:175.8pt;left:491.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">OA were safe and</span></p>
<p style="top:175.8pt;left:501.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">demonstrated satisfactory</span></p>
<p style="top:175.8pt;left:510.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">results in 63.2% of patients.</span></p>
<p style="top:184.3pt;left:519.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">No serious adverse events were</span></p>
<p style="top:175.8pt;left:528.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">reported.</span></p>
<p style="top:70.9pt;left:473.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">42</span></p>
<p style="top:33.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">532</span></p>
<p style="top:33.5pt;left:369.1pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">International Orthopaedics (SICOT) (2021) 45:525&#x2013;538</span></p>


<p style="top:56.8pt;left:306.1pt;line-height:12.0pt"><span style="font-family:LfwwglAdvTTaf7f9f4f.B,serif;font-size:12.0pt;color:#131313">Discussion</span></p>
<p style="top:83.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">The main finding of this systematic review is that the available</span></p>
<p style="top:95.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">preclinical and clinical studies suggest safety and overall pos-</span></p>
<p style="top:108.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">itive results of the injective treatment with BMAC in joints</span></p>
<p style="top:120.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">affected by OA. This research highlighted a growing number</span></p>
<p style="top:133.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of clinical trials published in the last years. Nevertheless, the</span></p>
<p style="top:145.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">literature analysis also underlined the limits of this young</span></p>
<p style="top:158.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">field, with only a few preclinical studies supporting the ratio-</span></p>
<p style="top:170.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">nale of BMAC injections, as well as an overall low quality of</span></p>
<p style="top:182.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">evidence of the clinical studies.</span></p>
<p style="top:195.3pt;left:317.5pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">BMAC is increasingly used as injective treatment of OA,</span></p>
<p style="top:207.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">with the rationale relying on the transplantation of the entire</span></p>
<p style="top:220.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">bone marrow niche which contains MSCs, haematopoietic</span></p>
<p style="top:232.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">precursors, monocytes, and endothelial cells, as well as a great</span></p>
<p style="top:245.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">array of soluble factors [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">14</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 49</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 50</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. BMSCs have the capacity</span></p>
<p style="top:257.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">to differentiate toward several lineages (i.e., chondrocytes,</span></p>
<p style="top:270.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">osteoblast, adipocytes) and to produce soluble factors, which</span></p>
<p style="top:282.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">may positively affect the joint homeostasis and eventually</span></p>
<p style="top:294.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">contribute to relief pain and to improve joint function [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">21</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span></p>
<p style="top:307.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">51</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 52</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. In particular, MSCs possess immunomodulatory, an-</span></p>
<p style="top:319.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ti-inflammatory, anti-apoptotic, proliferative, and</span></p>
<p style="top:332.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">chemoattractive functions, and can coordinate the differentia-</span></p>
<p style="top:344.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tion process of functional tissue regeneration in host cells [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">53</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">].</span></p>
<p style="top:357.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">However, the amount of BMSCs in BMA is not elevated, with</span></p>
<p style="top:369.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">a study investigating CD34</span><sup><span style="font-family:XnwwwtAdvTT3713a231+22,serif;font-size:7.0pt;color:#131313">&#x2212;</span></sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">, CD45</span><sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:7.0pt;color:#131313">low</span></sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">, and CD271</span><sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:7.0pt;color:#131313">high</span></sup><sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> </span></sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">posi-</span></p>
<p style="top:382.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tive cells underlying a low 0.04% rate [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">54</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Quantifying</span></p>
<p style="top:394.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">BMSCs has been historically based on the number of</span></p>
<p style="top:407.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">colony-forming units (CFU) that emerge from in vitro culture</span></p>
<p style="top:419.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of BMA samples, with studies estimating between 109 and</span></p>
<p style="top:431.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">664 CFU per milliliter of BMA [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">55</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. BMAC only slightly</span></p>
<p style="top:444.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">increases the concentration of BMSCs, leading to a much</span></p>
<p style="top:456.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">lower number of BMSCs compared with what was adminis-</span></p>
<p style="top:469.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tered in studies on the injection of expanded BMSCs, where a</span></p>
<p style="top:481.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">range from 5 &#xd7; 10</span><sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:7.0pt;color:#131313">6</span></sup><sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> </span></sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cell/ml to 24 &#xd7; 10</span><sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:7.0pt;color:#131313">6</span></sup><sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> </span></sup><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cell/ml [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">14</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] has been</span></p>
<p style="top:494.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">reported. Nevertheless, compared with cultured BMSCs,</span></p>
<p style="top:506.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">BMAC contains a high number of platelets rich in growth</span></p>
<p style="top:519.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">factors, cytokines, and chemokines, including transforming</span></p>
<p style="top:531.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">growth factor-beta (TGF-</span><span style="font-family:YbpclkAdvTT3713a231+03,serif;font-size:10.0pt;color:#131313">&#x3b2;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">), interleukin-1 receptor antagonist</span></p>
<p style="top:544.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(IL-1ra), platelet-derived growth factor (PDGF), bone mor-</span></p>
<p style="top:556.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">phogenetic protein (BMP)-2 and -7, and vascular endothelial</span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">growth factor (VEGF). These growth factors are involved in</span></p>
<p style="top:581.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">several pathways crucial for cell maintenance and function,</span></p>
<p style="top:593.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">for differentiation, for extracellular matrix production, and</span></p>
<p style="top:606.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">for the regulation of cell catabolic/anabolic activity [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">56</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">58</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">].</span></p>
<p style="top:618.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Accordingly, this combination of cells and bioactive proteins</span></p>
<p style="top:631.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">makes BMAC a unique product among the orthobiologics</span></p>
<p style="top:643.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">presently available, and may present the potential to alter the</span></p>
<p style="top:656.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">disease course and not just to decrease pain [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">59</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Beside this</span></p>
<p style="top:668.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">rationale, the increasing use of BMAC is also due to the severe</span></p>
<p style="top:681.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">restrictions and regulatory issues related to other strategies to</span></p>
<p style="top:693.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">exploit MSCs, which involve extended cell manipulation and</span></p>
<p style="top:705.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">in vitro cultivation. This, together with the risk of infection,</span></p>
<p style="top:708.1pt;left:52.1pt;line-height:8.5pt"><span style="font-family:XmhmcyAdvTTb8864ccf.B,serif;font-size:8.5pt;color:#131313">Table 2</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> (continued)</span></p>
<p style="top:708.1pt;left:71.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Author and</span></p>
<p style="top:708.1pt;left:81.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">year</span></p>
<p style="top:637.9pt;left:71.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Study design</span></p>
<p style="top:562.2pt;left:71.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Joint</span></p>
<p style="top:511.3pt;left:71.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Treatment</span></p>
<p style="top:421.9pt;left:71.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Harvest</span></p>
<p style="top:421.9pt;left:81.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">site</span></p>
<p style="top:376.1pt;left:71.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Bone</span></p>
<p style="top:376.1pt;left:81.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">marrow concentration</span></p>
<p style="top:376.1pt;left:91.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">and injected amount</span></p>
<p style="top:289.8pt;left:70.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Patient,</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> n</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> (M/F)</span></p>
<p style="top:289.8pt;left:81.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Age, mean</span></p>
<p style="top:281.3pt;left:91.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(SD or range)</span></p>
<p style="top:214.0pt;left:71.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">F-up</span></p>
<p style="top:185.5pt;left:71.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Results and adverse events</span></p>
<p style="top:72.1pt;left:71.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">mCMS</span></p>
<p style="top:707.8pt;left:110.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Centeno C et al.</span></p>
<p style="top:699.3pt;left:119.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2016 [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#0000ff">47</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">]</span></p>
<p style="top:637.6pt;left:110.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Retrospective</span></p>
<p style="top:629.1pt;left:119.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">comparative</span></p>
<p style="top:629.1pt;left:129.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">study</span></p>
<p style="top:562.0pt;left:110.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Knee</span></p>
<p style="top:562.0pt;left:119.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Hip</span></p>
<p style="top:562.0pt;left:129.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Ankle</span></p>
<p style="top:562.0pt;left:138.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Shoulder</span></p>
<p style="top:511.1pt;left:110.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">(A) BMAC + platelet</span></p>
<p style="top:502.6pt;left:119.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">products vs. (B)</span></p>
<p style="top:502.6pt;left:129.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC + platelet</span></p>
<p style="top:502.6pt;left:138.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">products + adipose</span></p>
<p style="top:502.6pt;left:147.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">graft vs. (C) cultured</span></p>
<p style="top:502.6pt;left:156.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">MSCs (pre-injection</span></p>
<p style="top:502.6pt;left:166.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">of dextrose)</span></p>
<p style="top:511.1pt;left:175.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Single IA injection</span></p>
<p style="top:421.7pt;left:110.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">PSIS</span></p>
<p style="top:375.9pt;left:110.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">The aspirate was</span></p>
<p style="top:367.4pt;left:119.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">processed in a sterile</span></p>
<p style="top:367.4pt;left:129.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">ISO-7 class clean</span></p>
<p style="top:367.4pt;left:138.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">room</span></p>
<p style="top:375.9pt;left:147.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">1</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.8pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">3 ml of BMAC</span></p>
<p style="top:367.4pt;left:156.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">containing</span></p>
<p style="top:375.9pt;left:166.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">0.2</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.8pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">1.5 &#xd7; 108</span></p>
<p style="top:367.4pt;left:175.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">nucleated cells</span></p>
<p style="top:284.5pt;left:110.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">A: 246 (134/113)</span></p>
<p style="top:277.5pt;left:119.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">60 years (11)</span></p>
<p style="top:286.4pt;left:129.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">B: 1589 (964/626)</span></p>
<p style="top:277.5pt;left:138.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">56 years (14)</span></p>
<p style="top:284.3pt;left:147.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">C: 535 (343/192)</span></p>
<p style="top:277.5pt;left:156.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">53 years (13)</span></p>
<p style="top:213.8pt;left:110.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">26 m</span></p>
<p style="top:185.3pt;left:110.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Adverse events were reported</span></p>
<p style="top:176.8pt;left:119.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">in 12.1% of the study</span></p>
<p style="top:176.8pt;left:129.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">population. Lowest rate of</span></p>
<p style="top:176.8pt;left:138.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">adverse events was among</span></p>
<p style="top:176.8pt;left:147.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">those patients receiving</span></p>
<p style="top:176.8pt;left:156.8pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC injections alone,</span></p>
<p style="top:176.8pt;left:166.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">compared with patients that</span></p>
<p style="top:176.8pt;left:175.3pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">received also adipose graft.</span></p>
<p style="top:71.8pt;left:110.5pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">24</span></p>
<p style="top:707.8pt;left:184.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Sampson S et al.</span></p>
<p style="top:699.3pt;left:193.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2016 [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#0000ff">48</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">]</span></p>
<p style="top:637.6pt;left:184.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Retrospective</span></p>
<p style="top:629.1pt;left:193.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">case series</span></p>
<p style="top:562.0pt;left:184.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Knee</span></p>
<p style="top:562.0pt;left:193.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Ankle</span></p>
<p style="top:562.0pt;left:203.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Hip</span></p>
<p style="top:562.0pt;left:212.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Shoulder</span></p>
<p style="top:511.1pt;left:184.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC</span></p>
<p style="top:511.1pt;left:193.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Single IA injection</span></p>
<p style="top:511.1pt;left:203.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">PRP injection</span></p>
<p style="top:502.6pt;left:212.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">after</span></p>
<p style="top:502.6pt;left:221.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">8 weeks</span></p>
<p style="top:421.7pt;left:184.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">PSIS</span></p>
<p style="top:375.9pt;left:184.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Thermo Scientific CL2</span></p>
<p style="top:367.4pt;left:193.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">centrifuge</span></p>
<p style="top:375.9pt;left:203.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">(MA, USA)</span></p>
<p style="top:375.9pt;left:212.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Larger joints: 5 ml of</span></p>
<p style="top:367.4pt;left:221.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">BMAC</span></p>
<p style="top:375.9pt;left:231.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">Smaller joints: 1</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.8pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">2 ml</span></p>
<p style="top:367.4pt;left:240.2pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">of BMAC</span></p>
<p style="top:261.1pt;left:184.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">125</span></p>
<p style="top:284.0pt;left:193.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">57 years (23</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.8pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">79)</span></p>
<p style="top:213.8pt;left:184.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">5 m</span></p>
<p style="top:185.3pt;left:184.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">IA injection of BMAC,</span></p>
<p style="top:176.8pt;left:193.9pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">followed by a PRP injection,</span></p>
<p style="top:176.8pt;left:203.1pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">provided short-term benefits</span></p>
<p style="top:176.8pt;left:212.4pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">in OA.</span></p>
<p style="top:185.3pt;left:221.7pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">No adverse events were</span></p>
<p style="top:176.8pt;left:231.0pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">reported.</span></p>
<p style="top:71.8pt;left:184.6pt;line-height:8.8pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.8pt;color:#131313">29</span></p>
<p style="top:708.1pt;left:260.1pt;line-height:8.5pt"><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313">ASIS</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> anterior superior iliac spine;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> BMAC</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> bone marrow aspirate concentrate;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> BMMNCs</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> bone marrow mononuclear cells;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> mCMS</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> modified Coleman Methodology Score;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> IA</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> intra-articular;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> LR</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> leukocyte rich;</span></p>
<p style="top:708.1pt;left:270.1pt;line-height:8.5pt"><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313">m</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> months;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> MFAT</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> micro-fragmented adipose tissue;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> MNCs</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> mononuclear cells;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> OA</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> osteoarthritis;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> PL</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> platelet lysate;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> PSIS</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> posterior superior iliac spine;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> PRP</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> platelet-rich plasma;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> RCT</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> randomized controlled</span></p>
<p style="top:708.1pt;left:280.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">trial;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> SD</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> standard deviation;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> TKA</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> total knee arthroplasty;</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> WBM</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> whole bone marrow</span></p>
<p style="top:33.5pt;left:532.3pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">533</span></p>
<p style="top:33.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">International Orthopaedics (SICOT) (2021) 45:525&#x2013;538</span></p>


<p style="top:58.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">contamination, or cell trans-differentiation [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">17</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">19</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], makes</span></p>
<p style="top:70.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cultured MSCs use extremely limited in the clinical practice</span></p>
<p style="top:83.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">both in Europe and in the USA [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">15</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. On the other hand, the</span></p>
<p style="top:95.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">use of BMAC is authorized by the US Food and Drug</span></p>
<p style="top:108.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Administration (FDA) because it is considered</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313"> &#x201c;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">minimally</span></p>
<p style="top:120.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">manipulated,</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x201d;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> although its use is foreseen only for a homolo-</span></p>
<p style="top:133.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">gous purpose and without involving a combination of cells or</span></p>
<p style="top:145.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tissues with another substance [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">15</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. According to this regula-</span></p>
<p style="top:158.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tory window, several different products have been proposed in</span></p>
<p style="top:170.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the clinical practice to produce BMAC.</span></p>
<p style="top:182.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">BMAC is frequently obtained through density gradient</span></p>
<p style="top:195.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">centrifugation of BMA, usually collected from the posterior</span></p>
<p style="top:207.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">or anterior iliac crest, and rarely from the distal femoral or</span></p>
<p style="top:220.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">proximal tibial metaphysis, the latter option being proposed</span></p>
<p style="top:232.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">in particular for knee pathology treatment [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">60</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. The harvest</span></p>
<p style="top:245.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">site may play an important role for the product obtained. In a</span></p>
<p style="top:257.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">recent study, Davies et al. [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">61</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] suggested that the pelvis was</span></p>
<p style="top:270.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">superior to femur and tibia in terms of the number of stem cells</span></p>
<p style="top:282.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">isolated, even though there was no significant difference in the</span></p>
<p style="top:294.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">phenotype of the cells isolated from different locations.</span></p>
<p style="top:307.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Moreover, Pierini et al. [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">62</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] demonstrated a higher quality</span></p>
<p style="top:319.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of BMA when it was collected from the posterior rather than</span></p>
<p style="top:332.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">anterior iliac crest in terms of number of colony-founding</span></p>
<p style="top:344.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">connective-tissue progenitors. Beside the anatomical site, oth-</span></p>
<p style="top:357.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">er factors can influence the quality of BMAC. Some authors</span></p>
<p style="top:369.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">reported a variable stem cell quantity and quality depending</span></p>
<p style="top:382.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">on age, including an age-related reduction in the absolute</span></p>
<p style="top:394.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">number of MSCs within BMA and a decreased proliferative</span></p>
<p style="top:407.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">and differentiative capacity [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">63</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 64</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Finally, the production</span></p>
<p style="top:419.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">process itself might influence the biological properties of</span></p>
<p style="top:431.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">BMAC. The collected BMA is usually centrifuged directly</span></p>
<p style="top:444.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">in the operating room, and nucleated cells (stem cells, mono-</span></p>
<p style="top:456.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cytes, lymphocytes) and proteins (growth factors, cytokines,</span></p>
<p style="top:469.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">and chemokines) are concentrated by removing most of the</span></p>
<p style="top:481.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">red cells and plasma. Then, BMA is reduced in volume with a</span></p>
<p style="top:494.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cell separator to obtain 3</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">8 ml of BMAC, and the final volume</span></p>
<p style="top:506.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">used will depend from the clinical application. Even though</span></p>
<p style="top:519.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">these steps are common to most of the procedures developed</span></p>
<p style="top:531.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">to obtain BMAC by BMA centrifugation, there are several</span></p>
<p style="top:544.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">commercial systems suitable for producing BMAC. The lack</span></p>
<p style="top:556.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of standardization of the producing techniques (such as differ-</span></p>
<p style="top:568.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ences in BMA starting volumes, centrifuge devices, and many</span></p>
<p style="top:581.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">other methodological differences) leads to several biological</span></p>
<p style="top:593.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">products with different progenitor cells and platelet number,</span></p>
<p style="top:606.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">other than different concentrations of growth factors and cy-</span></p>
<p style="top:618.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tokines [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">65</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 66</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. This aspect may hinder the possibility to</span></p>
<p style="top:631.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">compare literature results and to understand the real potential</span></p>
<p style="top:643.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of BMAC as OA injective treatment.</span></p>
<p style="top:656.1pt;left:62.4pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Despite the many still controversial aspects, BMAC is</span></p>
<p style="top:668.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">technically easy and presents the advantages of overcoming</span></p>
<p style="top:681.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the need for culture expansion, thus reducing the risk of in-</span></p>
<p style="top:693.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">fection and avoiding the risk of allogeneic diseases [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">67</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Thus,</span></p>
<p style="top:705.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">BMAC use is growing exponentially in the clinical practice</span></p>
<p style="top:58.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">for several orthopaedic procedures, including the treatment for</span></p>
<p style="top:70.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">OA [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">68</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 69</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. In a previous literature review, Di Matteo et al.</span></p>
<p style="top:83.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">underlined that currently BMAC, together with adipose</span></p>
<p style="top:95.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tissue-derived concentrates, were the most common strategies</span></p>
<p style="top:108.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">to exploit MSC potential through minimal manipulation, both</span></p>
<p style="top:120.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">showing promising results for knee OA, but also an overall</span></p>
<p style="top:133.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">poor methodology [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">65</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Nevertheless, it is important to under-</span></p>
<p style="top:145.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">line that, while a large literature is available for other types of</span></p>
<p style="top:158.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">BMAC applications, the clinical OA application is poorly</span></p>
<p style="top:170.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">justified by preclinical evidence on this specific treatment in-</span></p>
<p style="top:182.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">dication. Only few preclinical studies focused on the intra-</span></p>
<p style="top:195.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">articular injective use of BMAC for OA, while the majority</span></p>
<p style="top:207.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of these studies focused on culture-expanded BMSCs or on</span></p>
<p style="top:220.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">surgical applications of BMAC, including the treatment of</span></p>
<p style="top:232.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">focal cartilage defects (surgical augmentation or scaffold-</span></p>
<p style="top:245.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">based applications) [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">14</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 70</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 71</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. The few preclinical studies</span></p>
<p style="top:257.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">in the literature suggested that BMAC can affect OA progres-</span></p>
<p style="top:270.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">sion in the animal models, but they also underlined its limited</span></p>
<p style="top:282.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">potential, and the possibility to further exploit it through dif-</span></p>
<p style="top:294.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ferent production protocols as well as the combination of in-</span></p>
<p style="top:307.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">jective carriers to positively affect cell migration and favor</span></p>
<p style="top:319.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">longer-lasting homeostatic and disease-modifying effects</span></p>
<p style="top:332.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">[</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">51</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 72</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">].</span></p>
<p style="top:344.8pt;left:317.5pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">BMAC has been studied mainly for the knee injective treat-</span></p>
<p style="top:357.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ment, while only few studies focused on shoulder, hip, or</span></p>
<p style="top:369.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ankle OA. Overall, most of these studies converged on the</span></p>
<p style="top:382.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">safety and benefit of BMAC for OA symptom management.</span></p>
<p style="top:394.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Better results were found for BMAC injections against exer-</span></p>
<p style="top:407.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cise therapy in 48 patients with symptomatic knee OA, where</span></p>
<p style="top:419.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">this injective treatment suggested a greater impact on patients</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2019;</span></p>
<p style="top:431.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">knee function [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">35</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Moreover, BMAC injections were found</span></p>
<p style="top:444.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">to provide clinical results comparable with TKA in a popula-</span></p>
<p style="top:456.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tion of 30 young patients affected by osteonecrosis-related</span></p>
<p style="top:469.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">OA but with lower adverse events, thus suggesting, with all</span></p>
<p style="top:481.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the limits inherent of a small survey, the possibility to delay</span></p>
<p style="top:494.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">joint replacement through the application of a regenerative</span></p>
<p style="top:506.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">therapy [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">36</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. However, it is important to underline that no</span></p>
<p style="top:519.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">comparative study reported a superiority of BMAC against</span></p>
<p style="top:531.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">other injective treatments and, more importantly, the only</span></p>
<p style="top:544.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">available placebo-controlled RCT was not able to show any</span></p>
<p style="top:556.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">difference between BMAC- and saline-treated knees in pa-</span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tients with bilateral knee OA. Injective treatments, especially</span></p>
<p style="top:581.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313"> &#x201c;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">regenerative</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x201d;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> ones, present a high and long-lasting pla-</span></p>
<p style="top:593.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cebo effect [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">8</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], and high-level trials will have to prove that</span></p>
<p style="top:606.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">BMAC can exceed the mere placebo effect, to confirm the</span></p>
<p style="top:618.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">promising findings suggested by the published studies and</span></p>
<p style="top:631.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">justify its use in the clinical practice.</span></p>
<p style="top:643.7pt;left:317.5pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">A new application has been recently proposed to further</span></p>
<p style="top:656.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">exploit the potential of BMAC by targeting the subchondral</span></p>
<p style="top:668.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">bone which is commonly affected by the OA processes [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">36</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">].</span></p>
<p style="top:681.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">This strategy is supported by histological studies underlying</span></p>
<p style="top:693.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">different potential patterns of OA initiation, including initial</span></p>
<p style="top:705.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">subchondral bone alterations which may progress to the</span></p>
<p style="top:33.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">534</span></p>
<p style="top:33.5pt;left:369.1pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">International Orthopaedics (SICOT) (2021) 45:525&#x2013;538</span></p>


<p style="top:58.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">destruction of the overlying articular surface [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">73</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff"> 74</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">].</span></p>
<p style="top:70.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Accordingly, the subchondral bone is becoming more and</span></p>
<p style="top:83.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">more a target and subchondral injective therapies are gaining</span></p>
<p style="top:95.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">an increasing interest, ranging from bone substitutes to bio-</span></p>
<p style="top:108.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">logical treatments [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. In particular, some authors reported</span></p>
<p style="top:120.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the safety and effectiveness of subchondral PRP injections for</span></p>
<p style="top:133.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the treatment of severe knee and hip OA [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">76</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">78</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Sanchez</span></p>
<p style="top:145.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">et al. [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">79</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] suggested a superior clinical outcome at six and</span></p>
<p style="top:158.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">12 months for the combination of subchondral and intra-</span></p>
<p style="top:170.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">articular PRP injections when compared with intra-articular</span></p>
<p style="top:182.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">injections alone. The same authors suggested the possibility</span></p>
<p style="top:195.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of subchondral PRP injections to delay arthroplasty in severe</span></p>
<p style="top:207.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">knee OA [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">80</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Similarly, Vad et al. [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">81</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] showed an improve-</span></p>
<p style="top:220.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ment in pain and function in patients with knee OA treated</span></p>
<p style="top:232.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">with subchondral injections of BMA as an alternative to total</span></p>
<p style="top:245.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">knee replacement when other minimally invasive therapies</span></p>
<p style="top:257.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">have failed. Still, the subchondral application of BMAC has</span></p>
<p style="top:270.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">currently a limited scientific support and, as per intra-articular</span></p>
<p style="top:282.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">injections, more high-level studies are needed to understand</span></p>
<p style="top:294.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">if this could represent a valid option among biological treat-</span></p>
<p style="top:307.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ment strategies for OA.</span></p>
<p style="top:319.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">This systematic review presents several limitations</span></p>
<p style="top:332.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">reflecting the limitations of the available studies. In fact, the</span></p>
<p style="top:344.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">overall level of evidence was low; only four RCTs with a</span></p>
<p style="top:357.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">small size are available, while the other studies were retro-</span></p>
<p style="top:369.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">spective comparative studies or case series. Another signifi-</span></p>
<p style="top:382.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cant aspect is the absence of a proper control group compar-</span></p>
<p style="top:394.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ison, with only one placebo-controlled trial and overall few</span></p>
<p style="top:407.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">and heterogeneous comparative studies performed. Many dif-</span></p>
<p style="top:419.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ferences were documented among the included studies in</span></p>
<p style="top:431.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">terms of not standardized treatment protocols and different</span></p>
<p style="top:444.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">outcome measures. To this regard, many authors evaluated</span></p>
<p style="top:456.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">BMAC used with other orthobiologics, such as PRP or adi-</span></p>
<p style="top:469.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">pose tissue, hindering the possibility to isolate and assess the</span></p>
<p style="top:481.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">efficacy of BMAC as monotherapy. Moreover, BMAC prep-</span></p>
<p style="top:494.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">aration method, characteristics, and application modalities</span></p>
<p style="top:506.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(MSC count, injected amount, injection schedule) were often</span></p>
<p style="top:519.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">different or not even reported by the authors. In addition, most</span></p>
<p style="top:531.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of the studies used different scoring systems at different fol-</span></p>
<p style="top:544.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">low-ups, making it difficult to compare and merge results,</span></p>
<p style="top:556.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">thus impairing the possibility to perform a meta-analysis and</span></p>
<p style="top:568.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">to draw clear conclusions. Finally, the relatively short follow-</span></p>
<p style="top:581.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">up in most of these studies leaves concerns regarding the du-</span></p>
<p style="top:593.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">rability of the treatment results with BMAC for OA. Albeit</span></p>
<p style="top:606.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">being considered minimally invasive, this treatment still re-</span></p>
<p style="top:618.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">quires a surgical approach and results should prove significant</span></p>
<p style="top:631.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">and long-lasting to justify its use vs. less invasive homeostatic</span></p>
<p style="top:643.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">treatments [</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#0000ff">69</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">].</span></p>
<p style="top:656.1pt;left:62.4pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">In conclusion, this systematic review suggested a growing</span></p>
<p style="top:668.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">interest in the field of BMAC injections for the treatment of</span></p>
<p style="top:681.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">OA, with promising results in preclinical and clinical studies</span></p>
<p style="top:693.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">in terms of safety and effectiveness. Nevertheless, the current</span></p>
<p style="top:705.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">knowledge is still preliminary, the literature includes scarce</span></p>
<p style="top:58.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">preclinical evidence supporting BMAC rationale for this ap-</span></p>
<p style="top:70.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">plication, and clinical studies present significant heterogene-</span></p>
<p style="top:83.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ity, few patients, short-term follow-up, and overall poor meth-</span></p>
<p style="top:95.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">odology. Many aspects remain to be clarified to optimize the</span></p>
<p style="top:108.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">potential of BMAC, including methods of harvest, centrifuga-</span></p>
<p style="top:120.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tion, timing of injections, and application method, and to pro-</span></p>
<p style="top:133.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">vide a standardized method targeted for OA treatment.</span></p>
<p style="top:145.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Preclinical research is still needed to optimize BMAC use,</span></p>
<p style="top:158.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">as well as high-level large controlled trials to better understand</span></p>
<p style="top:170.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the real potential of BMAC injections for the treatment of</span></p>
<p style="top:182.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:10.0pt;color:#131313">patients affected by OA.</span></p>
<p style="top:207.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:8.5pt;color:#131313">Code availability</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Not applicable.</span></p>
<p style="top:229.4pt;left:306.1pt;line-height:8.5pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:8.5pt;color:#131313">Funding information</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Open access funding provided by Alma Mater</span></p>
<p style="top:239.4pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Studiorum - Universit&#xe0; di Bologna within the CRUI-CARE Agreement.</span></p>
<p style="top:249.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">This study was supported by the project</span><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> Giovane Ricercatore GR-2016-</span></p>
<p style="top:259.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:JjpttmAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313">02361990</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> funded by the Italian Ministry of Health.</span></p>
<p style="top:282.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:8.5pt;color:#131313">Data availability</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Not applicable.</span></p>
<p style="top:305.6pt;left:306.1pt;line-height:11.0pt"><span style="font-family:NsmfbfAdvTTa351d857.B,serif;font-size:11.0pt;color:#131313">Compliance with ethical standards</span></p>
<p style="top:330.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:8.5pt;color:#131313">Conflict of interest</span></p>
<p style="top:330.0pt;left:374.7pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Stefano Zaffagnini has received institutional support</span></p>
<p style="top:340.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">from Fidia Farmaceutici, Cartiheal, IGEA Clinical Biophysics, Biomet,</span></p>
<p style="top:349.9pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">and Kensey Nash; grant support from I+; and royalties from Springer.</span></p>
<p style="top:359.9pt;left:317.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">The other authors declare no conflict of interest.</span></p>
<p style="top:382.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:8.5pt;color:#131313">Ethics approval</span></p>
<p style="top:382.3pt;left:365.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Not applicable.</span></p>
<p style="top:404.8pt;left:306.1pt;line-height:8.5pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:8.5pt;color:#131313">Consent to participate</span></p>
<p style="top:404.8pt;left:388.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Not applicable.</span></p>
<p style="top:427.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:8.5pt;color:#131313">Consent for publication</span></p>
<p style="top:427.2pt;left:392.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Not applicable.</span></p>
<p style="top:446.5pt;left:306.1pt;line-height:8.0pt"><span style="font-family:WpftstAdvTT99c4c969,serif;font-size:8.0pt;color:#131313">Open Access</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> This article is licensed under a Creative Commons</span></p>
<p style="top:456.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Attribution 4.0 International License, which permits use, sharing, adap-</span></p>
<p style="top:466.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tation, distribution and reproduction in any medium or format, as long as</span></p>
<p style="top:476.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">you give appropriate credit to the original author(s) and the source, pro-</span></p>
<p style="top:485.9pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">vide a link to the Creative Commons licence, and indicate if changes were</span></p>
<p style="top:495.9pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">made. The images or other third party material in this article are included</span></p>
<p style="top:505.8pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">in the article&apos;s Creative Commons licence, unless indicated otherwise in a</span></p>
<p style="top:515.8pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">credit line to the material. If material is not included in the article&apos;s</span></p>
<p style="top:525.8pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Creative Commons licence and your intended use is not permitted by</span></p>
<p style="top:535.8pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">statutory regulation or exceeds the permitted use, you will need to obtain</span></p>
<p style="top:545.7pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">permission directly from the copyright holder. To view a copy of this</span></p>
<p style="top:555.7pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">licence, visit</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> http://creativecommons.org/licenses/by/4.0/</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">.</span></p>
<p style="top:614.6pt;left:306.1pt;line-height:12.0pt"><span style="font-family:LfwwglAdvTTaf7f9f4f.B,serif;font-size:12.0pt;color:#131313">References</span></p>
<p style="top:639.9pt;left:310.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1.</span></p>
<p style="top:639.9pt;left:325.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Mobasheri A, Batt M (2016) An update on the pathophysiology of</span></p>
<p style="top:649.9pt;left:325.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">osteoarthritis. Ann Phys Rehabil Med 59:333</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">339.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/</span></p>
<p style="top:659.9pt;left:325.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">10.1016/j.rehab.2016.07.004</span></p>
<p style="top:670.9pt;left:310.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">2.</span></p>
<p style="top:670.9pt;left:325.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Wallace IJ, Worthington S, Felson DT et al (2017) Knee osteoar-</span></p>
<p style="top:680.9pt;left:325.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">thritis has doubled in prevalence since the mid-20th century. Proc</span></p>
<p style="top:690.8pt;left:325.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Natl Acad Sci U S A 114:9332</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">9336.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1073/pnas.</span></p>
<p style="top:700.9pt;left:325.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">1703856114</span></p>
<p style="top:33.5pt;left:532.3pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">535</span></p>
<p style="top:33.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">International Orthopaedics (SICOT) (2021) 45:525&#x2013;538</span></p>


<p style="top:57.1pt;left:55.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">3.</span></p>
<p style="top:57.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Zhang Y, Jordan JM (2010) Epidemiology of osteoarthritis. Clin</span></p>
<p style="top:67.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Geriatr Med 26:355</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">369.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1016/j.cger.2010.03.</span></p>
<p style="top:77.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">001</span></p>
<p style="top:87.6pt;left:55.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">4.</span></p>
<p style="top:87.6pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Neogi T, Zhang Y (2013) Epidemiology of osteoarthritis. Rheum</span></p>
<p style="top:97.7pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Dis Clin N Am 39:1</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">19.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1016/j.rdc.2012.10.004</span></p>
<p style="top:108.2pt;left:55.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">5.</span></p>
<p style="top:108.2pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Goldring SR, Goldring MB (2006) Clinical aspects, pathology and</span></p>
<p style="top:118.2pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">pathophysiology of osteoarthritis. J Musculoskelet Neuronal</span></p>
<p style="top:128.2pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Interact 6:376</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">378</span></p>
<p style="top:138.8pt;left:55.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">6.</span></p>
<p style="top:138.8pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Filardo G, Kon E, Longo UG et al (2016) Non-surgical treatments</span></p>
<p style="top:148.7pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">for the management of early osteoarthritis. Knee Surg Sports</span></p>
<p style="top:158.8pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Traumatol Arthrosc 24:1775</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1785.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1007/</span></p>
<p style="top:168.7pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">s00167-016-4089-y</span></p>
<p style="top:179.3pt;left:55.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">7.</span></p>
<p style="top:179.3pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Losina E, Paltiel AD, Weinstein AM et al (2015) Lifetime medical</span></p>
<p style="top:189.3pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">costs of knee osteoarthritis management in the United States: im-</span></p>
<p style="top:199.3pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">pact of extending indications for total knee arthroplasty. Arthritis</span></p>
<p style="top:209.3pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Care Res (Hoboken) 67:203</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">215.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1002/acr.</span></p>
<p style="top:219.3pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">22412</span></p>
<p style="top:229.9pt;left:55.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">8.</span></p>
<p style="top:229.9pt;left:70.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Previtali D, Merli G, Di Laura FG, Candrian C, Zaffagnini S,</span></p>
<p style="top:239.8pt;left:70.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Filardo G (2020) The long-lasting effects of</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313"> &#x201c;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">placebo injections</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x201d;</span></p>
<p style="top:249.9pt;left:70.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">in knee osteoarthritis: a meta-analysis. Cartilage:</span></p>
<p style="top:259.9pt;left:70.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1947603520906597.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1177/1947603520906597</span></p>
<p style="top:270.4pt;left:55.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">9.</span></p>
<p style="top:270.4pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Filardo G, Previtali D, Napoli F, Candrian C, Zaffagnini S, Grassi A</span></p>
<p style="top:280.4pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2020) PRP injections for the treatment of knee osteoarthritis: a</span></p>
<p style="top:290.4pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">meta-analysis of randomized controlled trials. Cartilage:</span></p>
<p style="top:300.4pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1947603520931170.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1177/1947603520931170</span></p>
<p style="top:311.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">10.</span></p>
<p style="top:311.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Caplan AI (2005) Review: mesenchymal stem cells: cell-based re-</span></p>
<p style="top:321.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">constructive therapy in orthopedics. Tissue Eng 11:1198</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1211.</span></p>
<p style="top:330.9pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">https://doi.org/10.1089/ten.2005.11.1198</span></p>
<p style="top:341.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">11.</span></p>
<p style="top:341.5pt;left:70.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Chen FH, Tuan RS (2008) Mesenchymal stem cells in arthritic</span></p>
<p style="top:351.5pt;left:70.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">diseases. Arthritis Res Ther 10:223.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1186/ar2514</span></p>
<p style="top:362.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">12.</span></p>
<p style="top:362.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Kuci S, Henschler R, Muller I, Biagi E, Meisel R (2012) Basic</span></p>
<p style="top:372.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">biology and clinical application of multipotent mesenchymal stro-</span></p>
<p style="top:382.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">mal cells: from bench to bedside. Stem Cells Int 2012:185943.</span></p>
<p style="top:392.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">https://doi.org/10.1155/2012/185943</span></p>
<p style="top:402.7pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">13.</span></p>
<p style="top:402.7pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Friedenstein AJ, Piatetzky S II, Petrakova KV (1966) Osteogenesis</span></p>
<p style="top:412.6pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">in transplants of bone marrow cells. J Embryol Exp Morphol 16:</span></p>
<p style="top:422.6pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">381</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">390</span></p>
<p style="top:433.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">14.</span></p>
<p style="top:433.2pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Filardo G, Madry H, Jelic M, Roffi A, Cucchiarini M, Kon E (2013)</span></p>
<p style="top:443.2pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Mesenchymal stem cells for the treatment of cartilage lesions: from</span></p>
<p style="top:453.2pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">preclinical findings to clinical application in orthopaedics. Knee</span></p>
<p style="top:463.2pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Surg Sports Traumatol Arthrosc 21:1717</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1729.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.</span></p>
<p style="top:473.2pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">1007/s00167-012-2329-3</span></p>
<p style="top:483.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">15.</span></p>
<p style="top:483.8pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Administration FaD (2017) Regulatory considerations for human</span></p>
<p style="top:493.8pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">cells, tissues, and cellular and tissuebased products: minimal ma-</span></p>
<p style="top:503.7pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">nipulation and homologous use</span></p>
<p style="top:514.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">16.</span></p>
<p style="top:514.3pt;left:71.8pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Pagani S, Borsari V, Veronesi F et al (2017) Increased</span></p>
<p style="top:524.3pt;left:71.8pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">chondrogenic potential of mesenchymal cells from adipose tissue</span></p>
<p style="top:534.3pt;left:71.8pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">versus bone marrow-derived cells in osteoarthritic in vitro models.</span></p>
<p style="top:544.3pt;left:71.8pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">J Cell Physiol 232:1478</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1488.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1002/jcp.25651</span></p>
<p style="top:554.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">17.</span></p>
<p style="top:554.9pt;left:70.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Turner L, Knoepfler P (2016) Selling stem cells in the USA:</span></p>
<p style="top:564.9pt;left:70.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">assessing the direct-to-consumer industry. Cell Stem Cell 19:154</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span></p>
<p style="top:574.9pt;left:70.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">157.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1016/j.stem.2016.06.007</span></p>
<p style="top:585.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">18.</span></p>
<p style="top:585.4pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Song L, Tuan RS (2004) Transdifferentiation potential of human</span></p>
<p style="top:595.4pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">mesenchymal stem cells derived from bone marrow. FASEB J 18:</span></p>
<p style="top:605.5pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">980</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">982.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1096/fj.03-1100fje</span></p>
<p style="top:616.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">19.</span></p>
<p style="top:616.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Herberts CA, Kwa MS, Hermsen HP (2011) Risk factors in the</span></p>
<p style="top:626.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">development of stem cell therapy. J Transl Med 9:29.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.</span></p>
<p style="top:636.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">org/10.1186/1479-5876-9-29</span></p>
<p style="top:646.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">20.</span></p>
<p style="top:646.6pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Imam MA, Mahmoud SSS, Holton J, Abouelmaati D, Elsherbini Y,</span></p>
<p style="top:656.5pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Snow M (2017) A systematic review of the concept and clinical</span></p>
<p style="top:666.6pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">applications of bone marrow aspirate concentrate in orthopaedics.</span></p>
<p style="top:676.5pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">SICOT J 3:17.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1051/sicotj/2017007</span></p>
<p style="top:687.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">21.</span></p>
<p style="top:687.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Filardo G, Perdisa F, Roffi A, Marcacci M, Kon E (2016) Stem cells</span></p>
<p style="top:697.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">in articular cartilage regeneration. J Orthop Surg Res 11:42.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://</span></p>
<p style="top:707.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">doi.org/10.1186/s13018-016-0378-x</span></p>
<p style="top:57.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">22.</span></p>
<p style="top:57.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Bannuru RR, Osani MC, Vaysbrot EE et al (2019) OARSI guide-</span></p>
<p style="top:67.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">lines for the non-surgical management of knee, hip, and</span></p>
<p style="top:77.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">polyarticular osteoarthritis. Osteoarthr Cartil 27:1578</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1589.</span></p>
<p style="top:87.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">https://doi.org/10.1016/j.joca.2019.06.011</span></p>
<p style="top:97.8pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">23.</span></p>
<p style="top:97.8pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA state-</span></p>
<p style="top:107.8pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ment for reporting systematic reviews and meta-analyses of studies</span></p>
<p style="top:117.8pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">that evaluate health care interventions: explanation and elaboration.</span></p>
<p style="top:127.8pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">PLoS Med 6:e1000100.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1371/journal.pmed.</span></p>
<p style="top:137.8pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">1000100</span></p>
<p style="top:148.5pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">24.</span></p>
<p style="top:148.5pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Kon E, Verdonk P, Condello V et al (2009) Matrix-assisted autol-</span></p>
<p style="top:158.5pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ogous chondrocyte transplantation for the repair of cartilage defects</span></p>
<p style="top:168.5pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">of the knee: systematic clinical data review and study quality anal-</span></p>
<p style="top:178.5pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ysis. Am J Sports Med 37(Suppl 1):156S</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">166S.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.</span></p>
<p style="top:188.5pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">1177/0363546509351649</span></p>
<p style="top:199.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">25.</span></p>
<p style="top:199.2pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Malanga GA, Dona S, Borg-Stein J, Auriemma M, Singh JR (2018)</span></p>
<p style="top:209.2pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Refractory knee osteoarthritis: adipose-derived stromal cells versus</span></p>
<p style="top:219.2pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">bone marrow aspiration concentrate. PM R 10:524</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">532.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.</span></p>
<p style="top:229.2pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">org/10.1016/j.pmrj.2018.03.021</span></p>
<p style="top:240.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">26.</span></p>
<p style="top:240.0pt;left:326.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Shapiro SA, Kazmerchak SE, Heckman MG, Zubair AC,</span></p>
<p style="top:249.9pt;left:326.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">O</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2019;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Connor MI (2017) A prospective, single-blind, placebo-</span></p>
<p style="top:259.9pt;left:326.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">controlled trial of bone marrow aspirate concentrate for knee oste-</span></p>
<p style="top:269.9pt;left:326.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">oarthritis. Am J Sports Med 45:82</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">90.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1177/</span></p>
<p style="top:279.9pt;left:326.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">0363546516662455</span></p>
<p style="top:290.6pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">27.</span></p>
<p style="top:290.6pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Desando G, Bartolotti I, Cavallo C et al (2018) Short-term homing</span></p>
<p style="top:300.7pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">of hyaluronan-primed cells: therapeutic implications for osteoarthri-</span></p>
<p style="top:310.7pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tis treatment. Tissue Eng Part C Methods 24:121</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">133.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.</span></p>
<p style="top:320.6pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">org/10.1089/ten.TEC.2017.0336</span></p>
<p style="top:331.4pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">28.</span></p>
<p style="top:331.4pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Wang Z, Zhai C, Fei H et al (2018) Intraarticular injection autolo-</span></p>
<p style="top:341.4pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">gous platelet-rich plasma and bone marrow concentrate in a goat</span></p>
<p style="top:351.4pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">osteoarthritis model. J Orthop Res.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1002/jor.</span></p>
<p style="top:361.3pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">23877</span></p>
<p style="top:372.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">29.</span></p>
<p style="top:372.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Song F, Tang J, Geng R et al (2014) Comparison of the efficacy of</span></p>
<p style="top:382.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">bone marrow mononuclear cells and bone mesenchymal stem cells</span></p>
<p style="top:392.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">in the treatment of osteoarthritis in a sheep model. Int J Clin Exp</span></p>
<p style="top:402.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Pathol 7:1415</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1426</span></p>
<p style="top:412.8pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">30.</span></p>
<p style="top:412.8pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Singh A, Goel SC, Gupta KK et al (2014) The role of stem cells in</span></p>
<p style="top:422.8pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">osteoarthritis: an experimental study in rabbits. Bone Joint Res 3:</span></p>
<p style="top:432.8pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">32</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">37.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1302/2046-3758.32.2000187</span></p>
<p style="top:443.5pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">31.</span></p>
<p style="top:443.5pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Anz AW, Hubbard R, Rendos NK, Everts PA, Andrews JR, Hackel</span></p>
<p style="top:453.5pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">JG (2020) Bone marrow aspirate concentrate is equivalent to</span></p>
<p style="top:463.6pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">platelet-rich plasma for the treatment of knee osteoarthritis at 1 year:</span></p>
<p style="top:473.5pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">a prospective, randomized trial. Orthop J Sports Med 8:</span></p>
<p style="top:483.5pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">2325967119900958.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1177/2325967119900958</span></p>
<p style="top:494.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">32.</span></p>
<p style="top:494.3pt;left:325.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Mautner K, Bowers R, Easley K, Fausel Z, Robinson R (2019)</span></p>
<p style="top:504.3pt;left:325.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Functional outcomes following microfragmented adipose tissue</span></p>
<p style="top:514.2pt;left:325.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">versus bone marrow aspirate concentrate injections for symptomat-</span></p>
<p style="top:524.2pt;left:325.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ic knee osteoarthritis. Stem Cells Transl Med 8:1149</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1156.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://</span></p>
<p style="top:534.2pt;left:325.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">doi.org/10.1002/sctm.18-0285</span></p>
<p style="top:545.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">33.</span></p>
<p style="top:545.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Shapiro SA, Arthurs JR, Heckman MG et al (2019) Quantitative T2</span></p>
<p style="top:554.9pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">MRI mapping and 12-month follow-up in a randomized, blinded,</span></p>
<p style="top:565.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">placebo controlled trial of bone marrow aspiration and concentra-</span></p>
<p style="top:575.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tion for osteoarthritis of the knees. Cartilage 10:432</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">443.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://</span></p>
<p style="top:584.9pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">doi.org/10.1177/1947603518796142</span></p>
<p style="top:595.7pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">34.</span></p>
<p style="top:595.7pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Subasi V, Ekiz T (2019) Bone marrow aspiration concentrate and</span></p>
<p style="top:605.7pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">platelet-rich plasma in the treatment of knee osteoarthritis: a report</span></p>
<p style="top:615.7pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">of three cases. Complement Ther Clin Pract 34:113</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">115.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://</span></p>
<p style="top:625.7pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">doi.org/10.1016/j.ctcp.2018.11.005</span></p>
<p style="top:636.4pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">35.</span></p>
<p style="top:636.4pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Centeno C, Sheinkop M, Dodson E et al (2018) A specific protocol</span></p>
<p style="top:646.4pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">of autologous bone marrow concentrate and platelet products ver-</span></p>
<p style="top:656.4pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">sus exercise therapy for symptomatic knee osteoarthritis: a random-</span></p>
<p style="top:666.4pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ized controlled trial with 2 year follow-up. J Transl Med 16:355.</span></p>
<p style="top:676.4pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">https://doi.org/10.1186/s12967-018-1736-8</span></p>
<p style="top:687.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">36.</span></p>
<p style="top:687.2pt;left:325.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Hernigou P, Auregan JC, Dubory A, Flouzat-Lachaniette CH,</span></p>
<p style="top:697.1pt;left:325.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Chevallier N, Rouard H (2018) Subchondral stem cell therapy ver-</span></p>
<p style="top:707.1pt;left:325.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">sus contralateral total knee arthroplasty for osteoarthritis following</span></p>
<p style="top:33.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">536</span></p>
<p style="top:33.5pt;left:369.1pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">International Orthopaedics (SICOT) (2021) 45:525&#x2013;538</span></p>


<p style="top:57.1pt;left:70.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">secondary osteonecrosis of the knee. Int Orthop 42:2563</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">2571.</span></p>
<p style="top:67.1pt;left:70.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">https://doi.org/10.1007/s00264-018-3916-9</span></p>
<p style="top:77.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">37.</span></p>
<p style="top:77.8pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Shaw B, Darrow M, Derian A (2018) Short-term outcomes in treat-</span></p>
<p style="top:87.7pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ment of knee osteoarthritis with 4 bone marrow concentrate injec-</span></p>
<p style="top:97.8pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tions. Clin Med Insights Arthritis Musculoskelet Disord 11:</span></p>
<p style="top:107.7pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1179544118781080.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1177/1179544118781080</span></p>
<p style="top:118.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">38.</span></p>
<p style="top:118.5pt;left:70.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Themistocleous GS, Chloros GD, Kyrantzoulis IM et al (2018)</span></p>
<p style="top:128.4pt;left:70.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Effectiveness of a single intra-articular bone marrow aspirate con-</span></p>
<p style="top:138.4pt;left:70.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">centrate (BMAC) injection in patients with grade 3 and 4 knee</span></p>
<p style="top:148.4pt;left:70.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">osteoarthritis. Heliyon 4:e00871.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1016/j.heliyon.</span></p>
<p style="top:158.4pt;left:70.3pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">2018.e00871</span></p>
<p style="top:169.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">39.</span></p>
<p style="top:169.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Centeno CJ, Al-Sayegh H, Bashir J, Goodyear S, Freeman MD</span></p>
<p style="top:179.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2015) A dose response analysis of a specific bone marrow concen-</span></p>
<p style="top:189.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">trate treatment protocol for knee osteoarthritis. BMC Musculoskelet</span></p>
<p style="top:199.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Disord 16:258.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1186/s12891-015-0714-z</span></p>
<p style="top:209.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">40.</span></p>
<p style="top:209.8pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Centeno C, Pitts J, Al-Sayegh H, Freeman M (2014) Efficacy of</span></p>
<p style="top:219.8pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">autologous bone marrow concentrate for knee osteoarthritis with</span></p>
<p style="top:229.7pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">and without adipose graft. Biomed Res Int 2014:370621.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://</span></p>
<p style="top:239.7pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">doi.org/10.1155/2014/370621</span></p>
<p style="top:250.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">41.</span></p>
<p style="top:250.4pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Kim JD, Lee GW, Jung GH et al (2014) Clinical outcome of autol-</span></p>
<p style="top:260.4pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ogous bone marrow aspirates concentrate (BMAC) injection in de-</span></p>
<p style="top:270.4pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">generative arthritis of the knee. Eur J Orthop Surg Traumatol 24:</span></p>
<p style="top:280.4pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1505</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1511.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1007/s00590-013-1393-9</span></p>
<p style="top:291.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">42.</span></p>
<p style="top:291.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Darrow M, Shaw B, Darrow B, Wisz S (2018) Short-term outcomes</span></p>
<p style="top:301.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">of treatment of hip osteoarthritis with 4 bone marrow concentrate</span></p>
<p style="top:311.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">injections: a case series. Clin Med Insights Case Rep 11:</span></p>
<p style="top:321.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1179547618791574.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1177/1179547618791574</span></p>
<p style="top:331.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">43.</span></p>
<p style="top:331.8pt;left:70.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Centeno CPJ, Al-Sayegh H, Freeman MD (2014) Efficacy and</span></p>
<p style="top:341.8pt;left:70.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">safety of bone marrow concentrate for osteoarthritis of the hip;</span></p>
<p style="top:351.8pt;left:70.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">treatment registry results for 196 patients. J Stem Cell Res Ther 4:</span></p>
<p style="top:361.7pt;left:70.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">7.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.4172/2157-7633.1000242</span></p>
<p style="top:372.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">44.</span></p>
<p style="top:372.4pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Darrow MSB, Schmidt N, Boeger G, Budgett S (2019) Treatment</span></p>
<p style="top:382.4pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">of shoulder osteoarthritis and rotator cuff tears with bone marrow</span></p>
<p style="top:392.5pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">concentrate and whole bone marrow injections. Cogent Med Vol 6.</span></p>
<p style="top:402.4pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">https://doi.org/10.1080/2331205X.2019.1628883</span></p>
<p style="top:413.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">45.</span></p>
<p style="top:413.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Centeno CJ, Al-Sayegh H, Bashir J, Goodyear S, Freeman MD</span></p>
<p style="top:423.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2015) A prospective multi-site registry study of a specific protocol</span></p>
<p style="top:433.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">of autologous bone marrow concentrate for the treatment of shoul-</span></p>
<p style="top:443.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">der rotator cuff tears and osteoarthritis. J Pain Res 8:269</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">276.</span></p>
<p style="top:453.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">https://doi.org/10.2147/JPR.S80872</span></p>
<p style="top:463.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">46.</span></p>
<p style="top:463.8pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Rodriguez-Fontan F, Piuzzi NS, Kraeutler MJ, Pascual-Garrido C</span></p>
<p style="top:473.8pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2018) Early clinical outcomes of intra-articular injections of bone</span></p>
<p style="top:483.8pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">marrow aspirate concentrate for the treatment of early osteoarthritis</span></p>
<p style="top:493.8pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">of the hip and knee: a cohort study. PM R 10:1353</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1359.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://</span></p>
<p style="top:503.7pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">doi.org/10.1016/j.pmrj.2018.05.016</span></p>
<p style="top:514.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">47.</span></p>
<p style="top:514.5pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Centeno CJ, Al-Sayegh H, Freeman MD, Smith J, Murrell WD,</span></p>
<p style="top:524.4pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Bubnov R (2016) A multi-center analysis of adverse events among</span></p>
<p style="top:534.4pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">two thousand, three hundred and seventy two adult patients under-</span></p>
<p style="top:544.5pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">going adult autologous stem cell therapy for orthopaedic condi-</span></p>
<p style="top:554.4pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tions. Int Orthop 40:1755</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1765.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1007/s00264-</span></p>
<p style="top:564.4pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">016-3162-y</span></p>
<p style="top:575.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">48.</span></p>
<p style="top:575.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Sampson S, Smith J, Vincent H, Aufiero D, Zall M, Botto-van-</span></p>
<p style="top:585.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Bemden A (2016) Intra-articular bone marrow concentrate injection</span></p>
<p style="top:595.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">protocol: short-term efficacy in osteoarthritis. Regen Med 11:511</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span></p>
<p style="top:605.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">520.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.2217/rme-2016-0081</span></p>
<p style="top:615.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">49.</span></p>
<p style="top:615.8pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Fortier LA, Potter HG, Rickey EJ et al (2010) Concentrated bone</span></p>
<p style="top:625.8pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">marrow aspirate improves full-thickness cartilage repair compared</span></p>
<p style="top:635.8pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">with microfracture in the equine model. J Bone Joint Surg Am 92:</span></p>
<p style="top:645.8pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1927</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1937.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.2106/JBJS.I.01284</span></p>
<p style="top:656.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">50.</span></p>
<p style="top:656.4pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Johnson RG (2014) Bone marrow concentrate with allograft equiv-</span></p>
<p style="top:666.5pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">alent to autograft in lumbar fusions. Spine (Phila Pa 1976) 39:695</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span></p>
<p style="top:676.4pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">700.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1097/BRS.0000000000000254</span></p>
<p style="top:687.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">51.</span></p>
<p style="top:687.2pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Roffi A, Nakamura N, Sanchez M, Cucchiarini M, Filardo G (2018)</span></p>
<p style="top:697.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Injectable systems for intra-articular delivery of mesenchymal stro-</span></p>
<p style="top:707.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">mal cells for cartilage treatment: a systematic review of preclinical</span></p>
<p style="top:57.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">and clinical evidence. Int J Mol Sci 19.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.3390/</span></p>
<p style="top:67.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">ijms19113322</span></p>
<p style="top:77.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">52.</span></p>
<p style="top:77.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Lopa S, Colombini A, Moretti M, de Girolamo L (2019) Injective</span></p>
<p style="top:87.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">mesenchymal stem cell-based treatments for knee osteoarthritis:</span></p>
<p style="top:97.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">from mechanisms of action to current clinical evidences. Knee</span></p>
<p style="top:107.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Surg Sports Traumatol Arthrosc 27:2003</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">2020.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.</span></p>
<p style="top:117.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">1007/s00167-018-5118-9</span></p>
<p style="top:127.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">53.</span></p>
<p style="top:127.1pt;left:325.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Gaul F, Bugbee WD, Hoenecke HR Jr, D</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2019;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Lima DD (2019) A</span></p>
<p style="top:137.1pt;left:325.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">review of commercially available point-of-care devices to concen-</span></p>
<p style="top:147.1pt;left:325.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">trate bone marrow for the treatment of osteoarthritis and focal car-</span></p>
<p style="top:157.1pt;left:325.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tilage lesions. Cartilage 10:387</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">394.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1177/</span></p>
<p style="top:167.1pt;left:325.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">1947603518768080</span></p>
<p style="top:177.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">54.</span></p>
<p style="top:177.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">de Girolamo L, Bertolini G, Cervellin M, Sozzi G, Volpi P (2010)</span></p>
<p style="top:187.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Treatment of chondral defects of the knee with one step matrix-</span></p>
<p style="top:197.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">assisted technique enhanced by autologous concentrated bone mar-</span></p>
<p style="top:207.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">row: in vitro characterisation of mesenchymal stem cells from iliac</span></p>
<p style="top:217.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">crest and subchondral bone. Injury 41:1172</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1177.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/</span></p>
<p style="top:227.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">10.1016/j.injury.2010.09.027</span></p>
<p style="top:237.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">55.</span></p>
<p style="top:237.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Anz AW, Hackel JG, Nilssen EC, Andrews JR (2014) Application</span></p>
<p style="top:247.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">of biologics in the treatment of the rotator cuff, meniscus, cartilage,</span></p>
<p style="top:257.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">and osteoarthritis. J Am Acad Orthop Surg 22:68</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">79.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.</span></p>
<p style="top:267.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">org/10.5435/JAAOS-22-02-68</span></p>
<p style="top:277.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">56.</span></p>
<p style="top:277.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K (2002)</span></p>
<p style="top:287.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Two major Smad pathways in TGF-beta superfamily signalling.</span></p>
<p style="top:297.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Genes Cells 7:1191</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1204.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1046/j.1365-2443.</span></p>
<p style="top:307.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">2002.00599.x</span></p>
<p style="top:317.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">57.</span></p>
<p style="top:317.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Mariani E, Pulsatelli L, Facchini A (2014) Signaling pathways in</span></p>
<p style="top:327.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">cartilage repair. Int J Mol Sci 15:8667</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">8698.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.</span></p>
<p style="top:337.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">3390/ijms15058667</span></p>
<p style="top:347.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">58.</span></p>
<p style="top:347.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Fortier LA, Barker JU, Strauss EJ, McCarrel TM, Cole BJ (2011)</span></p>
<p style="top:357.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">The role of growth factors in cartilage repair. Clin Orthop Relat Res</span></p>
<p style="top:367.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">469:2706</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">2715.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1007/s11999-011-1857-3</span></p>
<p style="top:377.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">59.</span></p>
<p style="top:377.1pt;left:325.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Fortier LA, Strauss EJ, Shepard DO, Becktell L, Kennedy JG</span></p>
<p style="top:387.1pt;left:325.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2019) Biological effects of bone marrow concentrate in knee pa-</span></p>
<p style="top:397.1pt;left:325.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">thologies. J Knee Surg 32:2</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">8.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1055/s-0038-</span></p>
<p style="top:407.1pt;left:325.6pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">1676069</span></p>
<p style="top:417.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">60.</span></p>
<p style="top:417.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Shapiro SA, Arthurs JR (2017) Bone marrow aspiration for regen-</span></p>
<p style="top:427.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">erative orthopedic intervention: technique with ultrasound guidance</span></p>
<p style="top:437.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">for needle placement. Regen Med 12:917</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">928.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.</span></p>
<p style="top:447.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">2217/rme-2017-0109</span></p>
<p style="top:457.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">61.</span></p>
<p style="top:457.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Davies BM, Snelling SJB, Quek L et al (2017) Identifying the</span></p>
<p style="top:467.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">optimum source of mesenchymal stem cells for use in knee surgery.</span></p>
<p style="top:477.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">J Orthop Res 35:1868</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1875.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1002/jor.23501</span></p>
<p style="top:487.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">62.</span></p>
<p style="top:487.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Pierini M, Di Bella C, Dozza B et al (2013) The posterior iliac crest</span></p>
<p style="top:497.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">outperforms the anterior iliac crest when obtaining mesenchymal</span></p>
<p style="top:507.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">stem cells from bone marrow. J Bone Joint Surg Am 95:1101</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span></p>
<p style="top:517.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1107.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.2106/JBJS.L.00429</span></p>
<p style="top:527.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">63.</span></p>
<p style="top:527.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Stolzing A, Jones E, McGonagle D, Scutt A (2008) Age-related</span></p>
<p style="top:537.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">changes in human bone marrow-derived mesenchymal stem cells:</span></p>
<p style="top:547.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">consequences for cell therapies. Mech Ageing Dev 129:163</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">173.</span></p>
<p style="top:557.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">https://doi.org/10.1016/j.mad.2007.12.002</span></p>
<p style="top:567.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">64.</span></p>
<p style="top:567.1pt;left:326.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ,</span></p>
<p style="top:577.1pt;left:326.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Bellantuono I (2004) Study of telomere length reveals rapid aging</span></p>
<p style="top:587.1pt;left:326.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">of human marrow stromal cells following in vitro expansion. Stem</span></p>
<p style="top:597.1pt;left:326.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Cells 22:675</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">682.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1634/stemcells.22-5-675</span></p>
<p style="top:607.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">65.</span></p>
<p style="top:607.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Hegde V, Shonuga O, Ellis S et al (2014) A prospective comparison</span></p>
<p style="top:617.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">of 3 approved systems for autologous bone marrow concentration</span></p>
<p style="top:627.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">demonstrated nonequivalency in progenitor cell number and con-</span></p>
<p style="top:637.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">centration. J Orthop Trauma 28:591</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">598.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1097/</span></p>
<p style="top:647.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">BOT.0000000000000113</span></p>
<p style="top:657.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">66.</span></p>
<p style="top:657.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Dragoo JL, Guzman RA (2020) Evaluation of the consistency and</span></p>
<p style="top:667.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">composition of commercially available bone marrow aspirate con-</span></p>
<p style="top:677.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">centrate systems. Orthop J Sports Med 8:2325967119893634.</span></p>
<p style="top:687.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">https://doi.org/10.1177/2325967119893634</span></p>
<p style="top:697.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">67.</span></p>
<p style="top:697.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Chahla J, Dean CS, Moatshe G, Pascual-Garrido C, Serra Cruz R,</span></p>
<p style="top:707.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">LaPrade RF (2016) Concentrated bone marrow aspirate for the</span></p>
<p style="top:33.5pt;left:532.3pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">537</span></p>
<p style="top:33.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">International Orthopaedics (SICOT) (2021) 45:525&#x2013;538</span></p>


<p style="top:57.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">treatment of chondral injuries and osteoarthritis of the knee: a sys-</span></p>
<p style="top:67.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tematic review of outcomes. Orthop J Sports Med 4:</span></p>
<p style="top:77.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">2325967115625481.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1177/2325967115625481</span></p>
<p style="top:87.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">68.</span></p>
<p style="top:87.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Andriolo L, Merli G, Tobar C, Altamura SA, Kon E, Filardo G</span></p>
<p style="top:97.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2018) Regenerative therapies increase survivorship of avascular</span></p>
<p style="top:107.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">necrosis of the femoral head: a systematic review and meta-analy-</span></p>
<p style="top:117.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">sis. Int Orthop 42:1689</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1704.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1007/s00264-018-</span></p>
<p style="top:127.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">3787-0</span></p>
<p style="top:137.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">69.</span></p>
<p style="top:137.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Di Matteo B, Vandenbulcke F, Vitale ND et al (2019) Minimally</span></p>
<p style="top:147.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">manipulated mesenchymal stem cells for the treatment of knee os-</span></p>
<p style="top:157.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">teoarthritis: a systematic review of clinical evidence. Stem Cells Int</span></p>
<p style="top:167.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">2019:1735242.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1155/2019/1735242</span></p>
<p style="top:177.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">70.</span></p>
<p style="top:177.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Desando G, Giavaresi G, Cavallo C et al (2016) Autologous bone</span></p>
<p style="top:187.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">marrow concentrate in a sheep model of osteoarthritis: new perspec-</span></p>
<p style="top:197.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tives for cartilage and meniscus repair. Tissue Eng Part C Methods</span></p>
<p style="top:207.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">22:608</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">619.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1089/ten.TEC.2016.0033</span></p>
<p style="top:216.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">71.</span></p>
<p style="top:216.9pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Cavallo C, Desando G, Columbaro M et al (2013) Chondrogenic</span></p>
<p style="top:227.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">differentiation of bone marrow concentrate grown onto a</span></p>
<p style="top:237.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">hylauronan scaffold: rationale for its use in the treatment of cartilage</span></p>
<p style="top:246.9pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">lesions. J Biomed Mater Res A 101:1559</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1570.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.</span></p>
<p style="top:256.9pt;left:70.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">1002/jbm.a.34460</span></p>
<p style="top:266.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">72.</span></p>
<p style="top:266.9pt;left:70.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">D</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2019;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Arrigo D, Roffi A, Cucchiarini M, Moretti M, Candrian C,</span></p>
<p style="top:276.9pt;left:70.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Filardo G (2019) Secretome and extracellular vesicles as new bio-</span></p>
<p style="top:286.9pt;left:70.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">logical therapies for knee osteoarthritis: a systematic review. J Clin</span></p>
<p style="top:296.9pt;left:70.5pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Med 8.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.3390/jcm8111867</span></p>
<p style="top:306.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">73.</span></p>
<p style="top:306.9pt;left:71.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Mantripragada VP, Piuzzi NS, Zachos T, Obuchowski NA,</span></p>
<p style="top:316.9pt;left:71.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Muschler GF, Midura RJ (2018) High occurrence of osteoarthritic</span></p>
<p style="top:326.9pt;left:71.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">histopathological features unaccounted for by traditional scoring</span></p>
<p style="top:336.8pt;left:71.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">systems in lateral femoral condyles from total knee arthroplasty</span></p>
<p style="top:346.9pt;left:71.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">patients with varus alignment. Acta Orthop 89:197</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">203.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://</span></p>
<p style="top:356.9pt;left:71.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">doi.org/10.1080/17453674.2017.1398559</span></p>
<p style="top:366.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">74.</span></p>
<p style="top:366.8pt;left:71.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Mantripragada VP, Piuzzi NS, Zachos T, Obuchowski NA,</span></p>
<p style="top:376.8pt;left:71.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Muschler GF, Midura RJ (2017) Histopathological assessment of</span></p>
<p style="top:386.8pt;left:71.0pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">primary osteoarthritic knees in large patient cohort reveal the</span></p>
<p style="top:57.1pt;left:326.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">possibility of several potential patterns of osteoarthritis initiation.</span></p>
<p style="top:67.1pt;left:326.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Curr Res Transl Med 65:133</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">139.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1016/j.retram.</span></p>
<p style="top:77.1pt;left:326.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">2017.09.002</span></p>
<p style="top:88.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">75.</span></p>
<p style="top:88.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Sundaram K, Vargas-Hernandez JS, Sanchez TR et al (2019) Are</span></p>
<p style="top:98.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">subchondral intraosseous injections effective and safe for the treat-</span></p>
<p style="top:108.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ment of knee osteoarthritis? A systematic review. J Knee Surg 32:</span></p>
<p style="top:118.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1046</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1057.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1055/s-0039-1677792</span></p>
<p style="top:129.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">76.</span></p>
<p style="top:129.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Lychagin A, Lipina M, Garkavi A et al (2020) Intraosseous injec-</span></p>
<p style="top:138.9pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tions of platelet rich plasma for knee bone marrow lesions treat-</span></p>
<p style="top:148.9pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ment: one year follow-up. Int Orthop.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1007/</span></p>
<p style="top:158.9pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">s00264-020-04546-5</span></p>
<p style="top:169.8pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">77.</span></p>
<p style="top:169.8pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Su K, Bai Y, Wang J, Zhang H, Liu H, Ma S (2018) Comparison of</span></p>
<p style="top:179.9pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">hyaluronic acid and PRP intra-articular injection with combined</span></p>
<p style="top:189.8pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">intra-articular and intraosseous PRP injections to treat patients with</span></p>
<p style="top:199.8pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">knee osteoarthritis. Clin Rheumatol 37:1341</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1350.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/</span></p>
<p style="top:209.8pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff">10.1007/s10067-018-3985-6</span></p>
<p style="top:220.7pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">78.</span></p>
<p style="top:220.7pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Sanchez M, Delgado D, Sanchez P et al (2016) Combination of</span></p>
<p style="top:230.8pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">intra-articular and intraosseous injections of platelet rich plasma</span></p>
<p style="top:240.8pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">for severe knee osteoarthritis: a pilot study. Biomed Res Int 2016:</span></p>
<p style="top:250.7pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">4868613.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1155/2016/4868613</span></p>
<p style="top:261.7pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">79.</span></p>
<p style="top:261.7pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Sanchez M, Delgado D, Pompei O et al (2019) Treating severe knee</span></p>
<p style="top:271.7pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">osteoarthritis with combination of intra-osseous and intra-articular</span></p>
<p style="top:281.7pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">infiltrations of platelet-rich plasma: an observational study.</span></p>
<p style="top:291.7pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Cartilage 10:245</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">253.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1177/1947603518756462</span></p>
<p style="top:302.6pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">80.</span></p>
<p style="top:302.6pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Sanchez M, Fiz N, Guadilla J et al (2014) Intraosseous infiltration</span></p>
<p style="top:312.6pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">of platelet-rich plasma for severe knee osteoarthritis. Arthrosc Tech</span></p>
<p style="top:322.6pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">3:e713</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">e717.</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#0000ff"> https://doi.org/10.1016/j.eats.2014.09.006</span></p>
<p style="top:333.5pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">81.</span></p>
<p style="top:333.5pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">V. Vad RB, E. Linnell, and J. Harrison (2016) Knee osteoarthritis</span></p>
<p style="top:343.5pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">treated with percutaneous chondral-bone interface optimization: a</span></p>
<p style="top:353.5pt;left:325.2pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">pilot trial. Surg Sci 7:1</span><span style="font-family:ShstyfAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">12</span></p>
<p style="top:376.9pt;left:306.1pt;line-height:8.5pt"><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:8.5pt;color:#131313">Publisher</span><span style="font-family:VcspxsAdvTT577c760c+20,serif;font-size:8.5pt;color:#131313">&#x2019;</span><span style="font-family:CqjptdAdvTT577c760c,serif;font-size:8.5pt;color:#131313">s note</span><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Springer Nature remains neutral with regard to jurisdic-</span></p>
<p style="top:386.9pt;left:306.1pt;line-height:8.5pt"><span style="font-family:FxnhnlAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tional claims in published maps and institutional affiliations.</span></p>
<p style="top:33.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">538</span></p>
<p style="top:33.5pt;left:369.1pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">International Orthopaedics (SICOT) (2021) 45:525&#x2013;538</span></p>

</div>
